{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:58:01Z","timestamp":1793228281527,"version":"4.5.0"},"reference-count":387,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82430123"],"award-info":[{"award-number":["82430123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Collaborative Scientific and Technological Project of the Science and Technology Department of the National Administration of Traditional Chinese Medicine","award":["GZY-KJS-SD-2023-023"],"award-info":[{"award-number":["GZY-KJS-SD-2023-023"]}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tstp20221166"],"award-info":[{"award-number":["tstp20221166"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Joint Fund for Innovative Development of Shandong Natural ScienceFoundation","award":["ZR2023LZY006"],"award-info":[{"award-number":["ZR2023LZY006"]}]},{"name":"2025 Shandong University of Traditional Chinese Medicine Master's Degree Program Quality Enhancement and Innovation Project","award":["YJSTZCX2025183"],"award-info":[{"award-number":["YJSTZCX2025183"]}]},{"name":"The National Science and Technology Major Project","award":["2025ZD1800600"],"award-info":[{"award-number":["2025ZD1800600"]}]},{"name":"The National Administration of Traditional Chinese Medicine High-Level Key Discipline Construction Project of Traditional Chinese Medicine","award":["ZYYZDXK-2023125"],"award-info":[{"award-number":["ZYYZDXK-2023125"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic resistance remains a major cause of treatment failure and disease recurrence across cancer types, considerably limiting the long-term efficacy of chemotherapies, targeted therapies, and immunotherapies. Growing evidence indicates that resistance cannot be fully explained by static genetic alterations but rather arises from dynamic and reversible adaptive processes. Epigenetic regulation governs transcriptional plasticity, cellular state transitions, and tumor heterogeneity under therapeutic stress. Alterations in DNA methylation, histone modifications, chromatin accessibility, and non-coding RNA networks enable cancer cells to silence tumor suppressor programs, activate compensatory survival pathways, acquire stem cell-like drug-tolerant persister states, and remodel the tumor immune microenvironment. These mechanisms often act in a coordinated manner to form a dynamic regulatory system that supports adaptive resistance. However, current studies have frequently focused on individual epigenetic regulators and have lacked an integrated framework to explain how epigenetic plasticity collectively drives therapeutic resistance. In this review, we deconstruct cancer therapy resistance using the conceptual framework of the \u201cepigenetic landscape.\u201d We summarize the molecular functions and crosstalk among the major epigenetic layers and describe how this integrated network sustains key resistance-associated phenotypes. We also discuss emerging therapeutic strategies that target epigenetic plasticity, including epigenetic drugs, targeted protein degradation, epigenetic editing, and rational combination therapies. Overall, this review provides a systematic framework for understanding epigenetically mediated therapy resistance and highlights epigenetic plasticity as a therapeutic vulnerability for developing durable cancer treatments.<\/jats:p>","DOI":"10.1186\/s43556-026-00458-9","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:23:17Z","timestamp":1777450997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Epigenetic modifications in cancer drug resistance: molecular mechanisms and therapeutic interventions"],"prefix":"10.1186","volume":"7","author":[{"given":"Jingyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minpu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-8788","authenticated-orcid":false,"given":"Changgang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-0956","authenticated-orcid":false,"given":"Jing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"2","key":"458_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","volume":"4","author":"R Salgia","year":"2018","unstructured":"Salgia R, Kulkarni P. The genetic\/non-genetic duality of drug \u201cResistance\u201d in cancer. Trends Cancer. 2018;4(2):110\u20138. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.001.","journal-title":"Trends Cancer"},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","volume":"83","author":"H Fatma","year":"2022","unstructured":"Fatma H, Maurya SK, Siddique HR. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Semin Cancer Biol. 2022;83:166\u201376. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.008.","journal-title":"Semin Cancer Biol"},{"key":"458_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100821","volume":"61","author":"S Chen","year":"2022","unstructured":"Chen S, Zhao Y, Liu S, Zhang J, Assaraf YG, Cui W, et al. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resist Updat. 2022;61:100821. https:\/\/doi.org\/10.1016\/j.drup.2022.100821.","journal-title":"Drug Resist Updat"},{"issue":"22","key":"458_CR4","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.Can-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021;81(22):5589\u201395. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-1606.","journal-title":"Cancer Res"},{"issue":"1","key":"458_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.Cd-23-0530","volume":"14","author":"G Ciriello","year":"2024","unstructured":"Ciriello G, Magnani L, Aitken SJ, Akkari L, Behjati S, Hanahan D, et al. Cancer evolution: a multifaceted affair. Cancer Discov. 2024;14(1):36\u201348. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0530.","journal-title":"Cancer Discov"},{"issue":"4","key":"458_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ccell.2016.03.009","volume":"29","author":"T Mazor","year":"2016","unstructured":"Mazor T, Pankov A, Song JS, Costello JF. Intratumoral heterogeneity of the epigenome. Cancer Cell. 2016;29(4):440\u201351. https:\/\/doi.org\/10.1016\/j.ccell.2016.03.009.","journal-title":"Cancer Cell"},{"issue":"8","key":"458_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrgastro.2017.53","volume":"14","author":"N Padmanabhan","year":"2017","unstructured":"Padmanabhan N, Ushijima T, Tan P. How to stomach an epigenetic insult: the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol. 2017;14(8):467\u201378. https:\/\/doi.org\/10.1038\/nrgastro.2017.53.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"458_CR8","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1158\/0008-5472.Can-17-3146","volume":"78","author":"MR Yun","year":"2018","unstructured":"Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, et al. Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors. Cancer Res. 2018;78(12):3350\u201362. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-3146.","journal-title":"Cancer Res"},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","volume":"83","author":"L Guo","year":"2022","unstructured":"Guo L, Lee YT, Zhou Y, Huang Y. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol. 2022;83:487\u2013502. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.022.","journal-title":"Semin Cancer Biol"},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semcancer.2020.11.018","volume":"83","author":"F Li","year":"2022","unstructured":"Li F, Qasim S, Li D, Dou QP. Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. Semin Cancer Biol. 2022;83:335\u201352. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.018.","journal-title":"Semin Cancer Biol"},{"key":"458_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.09.023","volume":"114","author":"Z Huang","year":"2016","unstructured":"Huang Z, Huang Q, Ji L, Wang Y, Qi X, Liu L, et al. Epigenetic regulation of active Chinese herbal components for cancer prevention and treatment: A follow-up review. Pharmacol Res. 2016;114:1\u201312. https:\/\/doi.org\/10.1016\/j.phrs.2016.09.023.","journal-title":"Pharmacol Res"},{"issue":"8","key":"458_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/0008-5472.Can-22-0657","volume":"82","author":"SJ Clark","year":"2022","unstructured":"Clark SJ, Molloy PL. Early insights into cancer epigenetics: gene promoter hypermethylation emerges as a potential biomarker for cancer detection. Cancer Res. 2022;82(8):1461\u20133. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0657.","journal-title":"Cancer Res"},{"issue":"5","key":"458_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41419-018-0487-z","volume":"9","author":"L Gailhouste","year":"2018","unstructured":"Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis. 2018;9(5):468. https:\/\/doi.org\/10.1038\/s41419-018-0487-z.","journal-title":"Cell Death Dis"},{"issue":"4","key":"458_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20(4):854\u201367. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.007.","journal-title":"Cell Rep"},{"issue":"6330","key":"458_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.aam7304","volume":"355","author":"MA Dawson","year":"2017","unstructured":"Dawson MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science. 2017;355(6330):1147\u201352. https:\/\/doi.org\/10.1126\/science.aam7304.","journal-title":"Science"},{"issue":"10","key":"458_CR16","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41588-021-00926-8","volume":"53","author":"KC Johnson","year":"2021","unstructured":"Johnson KC, Anderson KJ, Courtois ET, Gujar AD, Barthel FP, Varn FS, et al. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet. 2021;53(10):1456\u201368. https:\/\/doi.org\/10.1038\/s41588-021-00926-8.","journal-title":"Nat Genet"},{"issue":"15","key":"458_CR17","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.Can-25-0999","volume":"85","author":"EA Oliveira","year":"2025","unstructured":"Oliveira EA, Milite S, Fernandez-Mateos J, Cresswell GD, Yara-Romero E, Vlachogiannis G, et al. Epigenetic heritability of cell plasticity drives cancer drug resistance through a one-to-many genotype-to-phenotype paradigm. Cancer Res. 2025;85(15):2921\u201338. https:\/\/doi.org\/10.1158\/0008-5472.Can-25-0999.","journal-title":"Cancer Res"},{"issue":"2","key":"458_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41571-024-00972-1","volume":"22","author":"SS Tolu","year":"2025","unstructured":"Tolu SS, Viny AD, Amengual JE, Pro B, Bates SE. Getting the right combination to break the epigenetic code. Nat Rev Clin Oncol. 2025;22(2):117\u201333. https:\/\/doi.org\/10.1038\/s41571-024-00972-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2021.01.009","volume":"83","author":"S Goel","year":"2022","unstructured":"Goel S, Bhatia V, Biswas T, Ateeq B. Epigenetic reprogramming during prostate cancer progression: a perspective from development. Semin Cancer Biol. 2022;83:136\u201351. https:\/\/doi.org\/10.1016\/j.semcancer.2021.01.009.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"458_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/ng.3811","volume":"49","author":"G Jenkinson","year":"2017","unstructured":"Jenkinson G, Pujadas E, Goutsias J, Feinberg AP. Potential energy landscapes identify the information-theoretic nature of the epigenome. Nat Genet. 2017;49(5):719\u201329. https:\/\/doi.org\/10.1038\/ng.3811.","journal-title":"Nat Genet"},{"issue":"7","key":"458_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206169","volume":"10","author":"J Zhang","year":"2023","unstructured":"Zhang J, Huang L, Ge G, Hu K. Emerging epigenetic-based nanotechnology for cancer therapy: modulating the tumor microenvironment. Adv Sci (Weinh). 2023;10(7):e2206169. https:\/\/doi.org\/10.1002\/advs.202206169.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"458_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrg.2017.57","volume":"18","author":"Y Atlasi","year":"2017","unstructured":"Atlasi Y, Stunnenberg HG. The interplay of epigenetic marks during stem cell differentiation and development. Nat Rev Genet. 2017;18(11):643\u201358. https:\/\/doi.org\/10.1038\/nrg.2017.57.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"458_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66. https:\/\/doi.org\/10.1186\/s12943-024-01967-3.","journal-title":"Mol Cancer"},{"issue":"1","key":"458_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-020-01682-z","volume":"39","author":"C Yang","year":"2020","unstructured":"Yang C, Zhang J, Ma Y, Wu C, Cui W, Wang L. Histone methyltransferase and drug resistance in cancers. J Exp Clin Cancer Res. 2020;39(1):173. https:\/\/doi.org\/10.1186\/s13046-020-01682-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10149","key":"458_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s0140-6736(18)31268-6","volume":"392","author":"Y Dor","year":"2018","unstructured":"Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(18)31268-6.","journal-title":"Lancet"},{"issue":"15","key":"458_CR26","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1093\/nar\/gkab605","volume":"49","author":"X Liu","year":"2021","unstructured":"Liu X, Weikum ER, Tilo D, Vinson C, Ortlund EA. Structural basis for glucocorticoid receptor recognition of both unmodified and methylated binding sites, precursors of a modern recognition element. Nucleic Acids Res. 2021;49(15):8923\u201333. https:\/\/doi.org\/10.1093\/nar\/gkab605.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"458_CR27","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1093\/nar\/gkw230","volume":"44","author":"JE Shin","year":"2016","unstructured":"Shin JE, Lin C, Lim HN. Horizontal transfer of DNA methylation patterns into bacterial chromosomes. Nucleic Acids Res. 2016;44(9):4460\u201371. https:\/\/doi.org\/10.1093\/nar\/gkw230.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"458_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.trecan.2020.02.007","volume":"6","author":"J Smith","year":"2020","unstructured":"Smith J, Sen S, Weeks RJ, Eccles MR, Chatterjee A. Promoter DNA hypermethylation and paradoxical gene activation. Trends Cancer. 2020;6(5):392\u2013406. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.007.","journal-title":"Trends Cancer"},{"issue":"1","key":"458_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41467-021-27690-x","volume":"13","author":"M Zhou","year":"2022","unstructured":"Zhou M, Coruh C, Xu G, Martins LM, Bourbousse C, Lambolez A, et al. The CLASSY family controls tissue-specific DNA methylation patterns in Arabidopsis. Nat Commun. 2022;13(1):244. https:\/\/doi.org\/10.1038\/s41467-021-27690-x.","journal-title":"Nat Commun"},{"issue":"11","key":"458_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012\u201327. https:\/\/doi.org\/10.1016\/j.tig.2021.05.002.","journal-title":"Trends Genet"},{"issue":"15","key":"458_CR31","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1158\/0008-5472.Can-17-0262","volume":"77","author":"S Cao","year":"2017","unstructured":"Cao S, Zhu X, Zhang C, Qian H, Schuttler HB, Gong J, et al. Competition between DNA methylation, nucleotide synthesis, and antioxidation in cancer versus normal tissues. Cancer Res. 2017;77(15):4185\u201395. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0262.","journal-title":"Cancer Res"},{"key":"458_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108640","volume":"258","author":"AV Lee","year":"2024","unstructured":"Lee AV, Nestler KA, Chiappinelli KB. Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol Ther. 2024;258:108640. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108640.","journal-title":"Pharmacol Ther"},{"key":"458_CR33","doi-asserted-by":"publisher","unstructured":"Sato T, Issa JJ, Kropf P. DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med. 2017;7(5). https:\/\/doi.org\/10.1101\/cshperspect.a026948.","DOI":"10.1101\/cshperspect.a026948"},{"key":"458_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","volume":"188","author":"K Agrawal","year":"2018","unstructured":"Agrawal K, Das V, Vyas P, Hajd\u00fach M. Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic. Pharmacol Ther. 2018;188:45\u201379. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.02.006.","journal-title":"Pharmacol Ther"},{"key":"458_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108614","volume":"256","author":"X Huang","year":"2024","unstructured":"Huang X, Chen Y, Xiao Q, Shang X, Liu Y. Chemical inhibitors targeting histone methylation readers. Pharmacol Ther. 2024;256:108614. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108614.","journal-title":"Pharmacol Ther"},{"issue":"16","key":"458_CR36","doi-asserted-by":"publisher","first-page":"13732","DOI":"10.1021\/jacs.5c01699","volume":"147","author":"T Nozaki","year":"2025","unstructured":"Nozaki T, Onoda M, Habazaki M, Takeuchi Y, Ishida H, Sato Y, et al. Designer catalyst-enabled regiodivergent histone acetylation. J Am Chem Soc. 2025;147(16):13732\u201343. https:\/\/doi.org\/10.1021\/jacs.5c01699.","journal-title":"J Am Chem Soc"},{"issue":"19","key":"458_CR37","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1021\/acs.accounts.1c00463","volume":"54","author":"X Li","year":"2021","unstructured":"Li X, Li XD. Integrative chemical biology approaches to deciphering the histone code: a problem-driven journey. Acc Chem Res. 2021;54(19):3734\u201347. https:\/\/doi.org\/10.1021\/acs.accounts.1c00463.","journal-title":"Acc Chem Res"},{"issue":"5","key":"458_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.tibs.2022.03.002","volume":"47","author":"KA Franklin","year":"2022","unstructured":"Franklin KA, Shields CE, Haynes KA. Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering. Trends Biochem Sci. 2022;47(5):417\u201332. https:\/\/doi.org\/10.1016\/j.tibs.2022.03.002.","journal-title":"Trends Biochem Sci"},{"issue":"46","key":"458_CR39","doi-asserted-by":"publisher","first-page":"20979","DOI":"10.1021\/jacs.2c06135","volume":"144","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Lin J, Liu Z, Tian G, Li XM, Jing Y, et al. Photo-cross-linking to delineate epigenetic interactome. J Am Chem Soc. 2022;144(46):20979\u201397. https:\/\/doi.org\/10.1021\/jacs.2c06135.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"458_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-025-00353-z","volume":"17","author":"M Hu","year":"2025","unstructured":"Hu M, Fan Z. Role and mechanisms of histone methylation in osteogenic\/odontogenic differentiation of dental mesenchymal stem cells. Int J Oral Sci. 2025;17(1):24. https:\/\/doi.org\/10.1038\/s41368-025-00353-z.","journal-title":"Int J Oral Sci"},{"key":"458_CR41","doi-asserted-by":"publisher","unstructured":"Brien GL, Bressan RB, Monger C, Gannon D, Lagan E, Doherty AM et al. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells. Nat Genet. 2021;53(8):1221\u201332. https:\/\/doi.org\/10.1038\/s41588-021-00897-w.","DOI":"10.1038\/s41588-021-00897-w"},{"issue":"4","key":"458_CR42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.molcel.2021.12.037","volume":"82","author":"A Barral","year":"2022","unstructured":"Barral A, Pozo G, Ducrot L, Papadopoulos GL, Sauzet S, Oldfield AJ, et al. SETDB1\/NSD-dependent H3K9me3\/H3K36me3 dual heterochromatin maintains gene expression profiles by bookmarking poised enhancers. Mol Cell. 2022;82(4):816-32.e12. https:\/\/doi.org\/10.1016\/j.molcel.2021.12.037.","journal-title":"Mol Cell"},{"key":"458_CR43","doi-asserted-by":"publisher","unstructured":"Murphy AE, Askarova A, Lenhard B, Skene NG, Marzi SJ. Predicting gene expression from histone marks using chromatin deep learning models depends on histone mark function, regulatory distance and cellular states. Nucleic Acids Res. 2025;53(4). https:\/\/doi.org\/10.1093\/nar\/gkae1212.","DOI":"10.1093\/nar\/gkae1212"},{"key":"458_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216706","volume":"586","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S. EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett. 2024;586:216706. https:\/\/doi.org\/10.1016\/j.canlet.2024.216706.","journal-title":"Cancer Lett"},{"issue":"5","key":"458_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41389-020-0234-z","volume":"9","author":"W Zhan","year":"2020","unstructured":"Zhan W, Liao X, Liu J, Tian T, Yu L, Li R. USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3. Oncogenesis. 2020;9(5):48. https:\/\/doi.org\/10.1038\/s41389-020-0234-z.","journal-title":"Oncogenesis"},{"issue":"6","key":"458_CR46","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.7150\/ijbs.109638","volume":"21","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Jing Y, Xu Z, Zhao H, He X, Lu T, et al. The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancer. Int J Biol Sci. 2025;21(6):2880\u201390. https:\/\/doi.org\/10.7150\/ijbs.109638.","journal-title":"Int J Biol Sci"},{"issue":"7754","key":"458_CR47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-019-1115-5","volume":"569","author":"D Barisic","year":"2019","unstructured":"Barisic D, Stadler MB, Iurlaro M, Sch\u00fcbeler D. Mammalian ISWI and SWI\/SNF selectively mediate binding of distinct transcription factors. Nature. 2019;569(7754):136\u201340. https:\/\/doi.org\/10.1038\/s41586-019-1115-5.","journal-title":"Nature"},{"issue":"1","key":"458_CR48","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1038\/s41467-021-26629-6","volume":"12","author":"H Jo","year":"2021","unstructured":"Jo H, Kim T, Chun Y, Jung I, Lee D. A compendium of chromatin contact maps reflecting regulation by chromatin remodelers in budding yeast. Nat Commun. 2021;12(1):6380. https:\/\/doi.org\/10.1038\/s41467-021-26629-6.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41467-024-55539-6","volume":"16","author":"JA Oo","year":"2025","unstructured":"Oo JA, Warwick T, P\u00e1lfi K, Lam F, McNicoll F, Prieto-Garcia C, et al. Long non-coding RNAs direct the SWI\/SNF complex to cell type-specific enhancers. Nat Commun. 2025;16(1):131. https:\/\/doi.org\/10.1038\/s41467-024-55539-6.","journal-title":"Nat Commun"},{"key":"458_CR50","doi-asserted-by":"publisher","unstructured":"Kanno SI, Kobayashi T, Watanabe R, Kurimasa A, Tanaka K, Yasui A et al. Armadillo domain of ARID1A directly interacts with DNA-PKcs to couple chromatin remodeling with nonhomologous end joining (NHEJ) pathway. Nucleic Acids Res. 2025;53(5). https:\/\/doi.org\/10.1093\/nar\/gkaf150.","DOI":"10.1093\/nar\/gkaf150"},{"issue":"7633","key":"458_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature20590","volume":"540","author":"L Yan","year":"2016","unstructured":"Yan L, Wang L, Tian Y, Xia X, Chen Z. Structure and regulation of the chromatin remodeller ISWI. Nature. 2016;540(7633):466\u20139. https:\/\/doi.org\/10.1038\/nature20590.","journal-title":"Nature"},{"issue":"10","key":"458_CR52","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.molcel.2025.04.020","volume":"85","author":"AM James","year":"2025","unstructured":"James AM, Farnung L. Structural basis of human CHD1 nucleosome recruitment and pausing. Mol Cell. 2025;85(10):1938-51.e6. https:\/\/doi.org\/10.1016\/j.molcel.2025.04.020.","journal-title":"Mol Cell"},{"issue":"11","key":"458_CR53","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.molcel.2022.04.026","volume":"82","author":"LJ Hsieh","year":"2022","unstructured":"Hsieh LJ, Gourdet MA, Moore CM, Mu\u00f1oz EN, Gamarra N, Ramani V, et al. A hexasome is the preferred substrate for the INO80 chromatin remodeling complex, allowing versatility of function. Mol Cell. 2022;82(11):2098-112.e4. https:\/\/doi.org\/10.1016\/j.molcel.2022.04.026.","journal-title":"Mol Cell"},{"issue":"9","key":"458_CR54","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tips.2025.07.008","volume":"46","author":"H Jing","year":"2025","unstructured":"Jing H, Zhang X, Meng L. Swinging the SWI\/SNF complexes for cancer therapy. Trends Pharmacol Sci. 2025;46(9):907\u201321. https:\/\/doi.org\/10.1016\/j.tips.2025.07.008.","journal-title":"Trends Pharmacol Sci"},{"issue":"22","key":"458_CR55","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1158\/0008-5472.Can-21-0206","volume":"81","author":"S Zhang","year":"2021","unstructured":"Zhang S, Zhou YF, Cao J, Burley SK, Wang HY, Zheng XFS. mTORC1 promotes ARID1A degradation and oncogenic chromatin remodeling in hepatocellular carcinoma. Cancer Res. 2021;81(22):5652\u201365. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-0206.","journal-title":"Cancer Res"},{"issue":"7","key":"458_CR56","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/0008-5472.Can-23-2244","volume":"84","author":"A Chaudhri","year":"2024","unstructured":"Chaudhri A, Lizee G, Hwu P, Rai K. Chromatin remodelers are regulators of the tumor immune microenvironment. Cancer Res. 2024;84(7):965\u201376. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-2244.","journal-title":"Cancer Res"},{"issue":"8","key":"458_CR57","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023;41(8):1516-34.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.005.","journal-title":"Cancer Cell"},{"key":"458_CR58","doi-asserted-by":"publisher","first-page":"14648","DOI":"10.1038\/ncomms14648","volume":"8","author":"BH Alver","year":"2017","unstructured":"Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, et al. The SWI\/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nat Commun. 2017;8:14648. https:\/\/doi.org\/10.1038\/ncomms14648.","journal-title":"Nat Commun"},{"key":"458_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108956","volume":"277","author":"S Das","year":"2026","unstructured":"Das S, Chatterjee S, Patel T, Banerjee S. RNA renaissance: harnessing non-coding RNA therapeutics for hepatocellular carcinoma. Pharmacol Ther. 2026;277:108956. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108956.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"458_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41580-024-00818-9","volume":"26","author":"K Jouravleva","year":"2025","unstructured":"Jouravleva K, Zamore PD. A guide to the biogenesis and functions of endogenous small non-coding RNAs in animals. Nat Rev Mol Cell Biol. 2025;26(5):347\u201370. https:\/\/doi.org\/10.1038\/s41580-024-00818-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"14","key":"458_CR61","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1093\/nar\/gkw139","volume":"44","author":"MS Weinberg","year":"2016","unstructured":"Weinberg MS, Morris KV. Transcriptional gene silencing in humans. Nucleic Acids Res. 2016;44(14):6505\u201317. https:\/\/doi.org\/10.1093\/nar\/gkw139.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"458_CR62","doi-asserted-by":"publisher","first-page":"8515","DOI":"10.1093\/nar\/gkae416","volume":"52","author":"NA Verheyden","year":"2024","unstructured":"Verheyden NA, Klostermann M, Br\u00fcggemann M, Steede HM, Scholz A, Amr S, et al. A high-resolution map of functional miR-181 response elements in the thymus reveals the role of coding sequence targeting and an alternative seed match. Nucleic Acids Res. 2024;52(14):8515\u201333. https:\/\/doi.org\/10.1093\/nar\/gkae416.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"458_CR63","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/nar\/gkad1142","volume":"52","author":"C Diener","year":"2024","unstructured":"Diener C, Keller A, Meese E. The miRNA-target interactions: an underestimated intricacy. Nucleic Acids Res. 2024;52(4):1544\u201357. https:\/\/doi.org\/10.1093\/nar\/gkad1142.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"458_CR64","doi-asserted-by":"publisher","first-page":"W176","DOI":"10.1093\/nar\/gkw443","volume":"44","author":"P Furi\u00f3-Tar\u00ed","year":"2016","unstructured":"Furi\u00f3-Tar\u00ed P, Tarazona S, Gabald\u00f3n T, Enright AJ, Conesa A. spongeScan: A web for detecting microRNA binding elements in lncRNA sequences. Nucleic Acids Res. 2016;44(W1):W176\u201380. https:\/\/doi.org\/10.1093\/nar\/gkw443.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"458_CR65","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrg.2016.20","volume":"17","author":"DW Thomson","year":"2016","unstructured":"Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272\u201383. https:\/\/doi.org\/10.1038\/nrg.2016.20.","journal-title":"Nat Rev Genet"},{"key":"458_CR66","doi-asserted-by":"publisher","unstructured":"Guo JK, Blanco MR, Walkup WGt, Bonesteele G, Urbinati CR, Banerjee AK et al. Denaturing purifications demonstrate that PRC2 and other widely reported chromatin proteins do not appear to bind directly to RNA in\u00a0vivo. Mol Cell. 2024;84(7):1271\u201389.e12. https:\/\/doi.org\/10.1016\/j.molcel.2024.01.026.","DOI":"10.1016\/j.molcel.2024.01.026"},{"issue":"3","key":"458_CR67","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41596-018-0115-5","volume":"14","author":"J Lin","year":"2019","unstructured":"Lin J, Wen Y, He S, Yang X, Zhang H, Zhu H. Pipelines for cross-species and genome-wide prediction of long noncoding RNA binding. Nat Protoc. 2019;14(3):795\u2013818. https:\/\/doi.org\/10.1038\/s41596-018-0115-5.","journal-title":"Nat Protoc"},{"issue":"18","key":"458_CR68","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2017-06-788695","volume":"130","author":"JR Alvarez-Dominguez","year":"2017","unstructured":"Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965\u201375. https:\/\/doi.org\/10.1182\/blood-2017-06-788695.","journal-title":"Blood"},{"key":"458_CR69","doi-asserted-by":"publisher","unstructured":"Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genom Proteomics Bioinformatics. 2017;15(3):177\u201386. https:\/\/doi.org\/10.1016\/j.gpb.2016.12.005.","DOI":"10.1016\/j.gpb.2016.12.005"},{"key":"458_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.108049","volume":"222","author":"G Chen","year":"2025","unstructured":"Chen G, He Q, Xiao Q, Ai J, Qin Z, Zhong Z, et al. The role of Chinese medicines in targeting non-coding RNAs to overcome cancer drug resistance: mechanisms and clinical translation challenges. Pharmacol Res. 2025;222:108049. https:\/\/doi.org\/10.1016\/j.phrs.2025.108049.","journal-title":"Pharmacol Res"},{"issue":"2","key":"458_CR71","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.gpb.2022.10.003","volume":"21","author":"T Tang","year":"2023","unstructured":"Tang T, Liu X, Wu R, Shen L, Ren S, Shen B. CTRR-ncRNA: a knowledgebase for cancer therapy resistance and recurrence associated non-coding RNAs. Genomics Proteomics Bioinformatics. 2023;21(2):292\u20139. https:\/\/doi.org\/10.1016\/j.gpb.2022.10.003.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"458_CR72","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.apsb.2019.11.009","volume":"10","author":"L Liang","year":"2020","unstructured":"Liang L, Fu J, Wang S, Cen H, Zhang L, Mandukhail SR, et al. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B. 2020;10(6):1036\u201346. https:\/\/doi.org\/10.1016\/j.apsb.2019.11.009.","journal-title":"Acta Pharm Sin B"},{"key":"458_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100683","volume":"50","author":"W Jiang","year":"2020","unstructured":"Jiang W, Xia J, Xie S, Zou R, Pan S, Wang ZW, et al. Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resist Updat. 2020;50:100683. https:\/\/doi.org\/10.1016\/j.drup.2020.100683.","journal-title":"Drug Resist Updat"},{"key":"458_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100851","volume":"63","author":"D Singh","year":"2022","unstructured":"Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updat. 2022;63:100851. https:\/\/doi.org\/10.1016\/j.drup.2022.100851.","journal-title":"Drug Resist Updat"},{"issue":"11","key":"458_CR75","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","volume":"12","author":"H Ling","year":"2013","unstructured":"Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847\u201365. https:\/\/doi.org\/10.1038\/nrd4140.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"458_CR76","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41467-020-14604-6","volume":"11","author":"L Guo","year":"2020","unstructured":"Guo L, Li J, Zeng H, Guzman AG, Li T, Lee M, et al. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. Nat Commun. 2020;11(1):740. https:\/\/doi.org\/10.1038\/s41467-020-14604-6.","journal-title":"Nat Commun"},{"issue":"6","key":"458_CR77","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1158\/1078-0432.Ccr-23-2368","volume":"30","author":"Y Wang","year":"2024","unstructured":"Wang Y, Situ X, Cardenas H, Siu E, Alhunayan SA, Keathley R, et al. Preclinical evaluation of NTX-301, a novel DNA hypomethylating agent in ovarian cancer. Clin Cancer Res. 2024;30(6):1175\u201388. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2368.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"458_CR78","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s43556-025-00373-5","volume":"6","author":"C Ma","year":"2025","unstructured":"Ma C, Cheng J, Gu J, Wang Q. Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. Mol Biomed. 2025;6(1):132. https:\/\/doi.org\/10.1186\/s43556-025-00373-5.","journal-title":"Mol Biomed"},{"issue":"1","key":"458_CR79","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.apsb.2016.09.002","volume":"7","author":"X An","year":"2017","unstructured":"An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7(1):38\u201351. https:\/\/doi.org\/10.1016\/j.apsb.2016.09.002.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"458_CR80","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/0008-5472.Can-19-0819","volume":"80","author":"CW Chen","year":"2020","unstructured":"Chen CW, Fu M, Du ZH, Zhao F, Yang WW, Xu LH, et al. Long noncoding RNA MRPL23-AS1 promotes adenoid cystic carcinoma lung metastasis. Cancer Res. 2020;80(11):2273\u201385. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-0819.","journal-title":"Cancer Res"},{"key":"458_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100770","volume":"57","author":"L Gao","year":"2021","unstructured":"Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57:100770. https:\/\/doi.org\/10.1016\/j.drup.2021.100770.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"458_CR82","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1038\/s41418-020-0514-3","volume":"27","author":"B Yang","year":"2020","unstructured":"Yang B, Zhang B, Cao Z, Xu X, Huo Z, Zhang P, et al. The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy. Cell Death Differ. 2020;27(8):2433\u201350. https:\/\/doi.org\/10.1038\/s41418-020-0514-3.","journal-title":"Cell Death Differ"},{"key":"458_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101152","volume":"77","author":"S Luo","year":"2024","unstructured":"Luo S, Yue M, Wang D, Lu Y, Wu Q, Jiang J. Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer. Drug Resist Updat. 2024;77:101152. https:\/\/doi.org\/10.1016\/j.drup.2024.101152.","journal-title":"Drug Resist Updat"},{"issue":"4","key":"458_CR84","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2024.12.003","volume":"107","author":"A Catalano","year":"2025","unstructured":"Catalano A, Haas LS, Zodel K, Adlesic M, Cuomo F, Peighambari A, et al. Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma. Kidney Int. 2025;107(4):666\u201386. https:\/\/doi.org\/10.1016\/j.kint.2024.12.003.","journal-title":"Kidney Int"},{"issue":"10","key":"458_CR85","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1158\/0008-5472.Can-17-2466","volume":"78","author":"ML Schmidt","year":"2018","unstructured":"Schmidt ML, Hobbing KR, Donninger H, Clark GJ. RASSF1A deficiency enhances RAS-driven lung tumorigenesis. Cancer Res. 2018;78(10):2614\u201323. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2466.","journal-title":"Cancer Res"},{"issue":"8","key":"458_CR86","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41418-018-0211-7","volume":"26","author":"W Li","year":"2019","unstructured":"Li W, Yue F, Dai Y, Shi B, Xu G, Jiang X, et al. Suppressor of hepatocellular carcinoma RASSF1A activates autophagy initiation and maturation. Cell Death Differ. 2019;26(8):1379\u201395. https:\/\/doi.org\/10.1038\/s41418-018-0211-7.","journal-title":"Cell Death Differ"},{"issue":"14","key":"458_CR87","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1158\/0008-5472.Can-19-3853","volume":"80","author":"KK Slemmons","year":"2020","unstructured":"Slemmons KK, Yeung C, Baumgart JT, Juarez JOM, McCalla A, Helman LJ. Targeting hippo-dependent and hippo-independent YAP1 signaling for the treatment of childhood rhabdomyosarcoma. Cancer Res. 2020;80(14):3046\u201356. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-3853.","journal-title":"Cancer Res"},{"issue":"24","key":"458_CR88","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.Can-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards AC, Stalnecker CA, Jean Morales A, Taylor KE, Klomp JE, Klomp JA, et al. TEAD inhibition overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res. 2023;83(24):4112\u201329. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-2994.","journal-title":"Cancer Res"},{"issue":"11","key":"458_CR89","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/cac2.12609","volume":"44","author":"J Jiang","year":"2024","unstructured":"Jiang J, Ye P, Sun N, Zhu W, Yang M, Yu M, et al. Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma. Cancer Commun (Lond). 2024;44(11):1350\u201373. https:\/\/doi.org\/10.1002\/cac2.12609.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"458_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/2159-8290.Cd-20-1354","volume":"11","author":"A Italiano","year":"2021","unstructured":"Italiano A. ATR inhibition as an attractive therapeutic resource against cancer. Cancer Discov. 2021;11(1):14\u20136. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1354.","journal-title":"Cancer Discov"},{"issue":"1","key":"458_CR91","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1038\/s41467-018-06925-4","volume":"9","author":"M Ratnaparkhe","year":"2018","unstructured":"Ratnaparkhe M, Wong JKL, Wei PC, Hlevnjak M, Kolb T, Simovic M, et al. Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. Nat Commun. 2018;9(1):4760. https:\/\/doi.org\/10.1038\/s41467-018-06925-4.","journal-title":"Nat Commun"},{"issue":"6","key":"458_CR92","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/0008-5472.Can-17-1650","volume":"78","author":"E Curry","year":"2018","unstructured":"Curry E, Zeller C, Masrour N, Patten DK, Gallon J, Wilhelm-Benartzi CS, et al. Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis. Cancer Res. 2018;78(6):1383\u201391. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1650.","journal-title":"Cancer Res"},{"issue":"11","key":"458_CR93","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41422-018-0097-4","volume":"28","author":"F Yan","year":"2018","unstructured":"Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N, et al. A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018;28(11):1062\u201376. https:\/\/doi.org\/10.1038\/s41422-018-0097-4.","journal-title":"Cell Res"},{"issue":"1","key":"458_CR94","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reutersw\u00e4rd C, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020;11(1):3747. https:\/\/doi.org\/10.1038\/s41467-020-17537-2.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR95","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970. https:\/\/doi.org\/10.1038\/s41467-018-05564-z.","journal-title":"Nat Commun"},{"issue":"11","key":"458_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100674","volume":"4","author":"K O'Neill","year":"2024","unstructured":"O\u2019Neill K, Pleasance E, Fan J, Akbari V, Chang G, Dixon K, et al. Long-read sequencing of an advanced cancer cohort resolves rearrangements, unravels haplotypes, and reveals methylation landscapes. Cell Genom. 2024;4(11):100674. https:\/\/doi.org\/10.1016\/j.xgen.2024.100674.","journal-title":"Cell Genom"},{"issue":"6","key":"458_CR97","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.molcel.2019.06.020","volume":"75","author":"DS Kim","year":"2019","unstructured":"Kim DS, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL. Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21. Mol Cell. 2019;75(6):1270-85.e14. https:\/\/doi.org\/10.1016\/j.molcel.2019.06.020.","journal-title":"Mol Cell"},{"issue":"1","key":"458_CR98","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1038\/s41467-023-40779-9","volume":"14","author":"AB Sharma","year":"2023","unstructured":"Sharma AB, Ramlee MK, Kosmin J, Higgs MR, Wolstenholme A, Ronson GE, et al. C16orf72\/HAPSTR1\/TAPR1 functions with BRCA1\/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption. Nat Commun. 2023;14(1):5003. https:\/\/doi.org\/10.1038\/s41467-023-40779-9.","journal-title":"Nat Commun"},{"issue":"8","key":"458_CR99","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/annonc\/mdy197","volume":"29","author":"F Morano","year":"2018","unstructured":"Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, et al. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Ann Oncol. 2018;29(8):1800\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdy197.","journal-title":"Ann Oncol"},{"key":"458_CR100","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.semcancer.2019.11.011","volume":"65","author":"Y Kobayashi","year":"2020","unstructured":"Kobayashi Y, Lim SO, Yamaguchi H. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Semin Cancer Biol. 2020;65:51\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2019.11.011.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"458_CR101","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.trecan.2017.04.004","volume":"3","author":"EN Wainwright","year":"2017","unstructured":"Wainwright EN, Scaffidi P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer. 2017;3(5):372\u201386. https:\/\/doi.org\/10.1016\/j.trecan.2017.04.004.","journal-title":"Trends Cancer"},{"issue":"14","key":"458_CR102","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.7150\/thno.42523","volume":"10","author":"D Ravindran Menon","year":"2020","unstructured":"Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020;10(14):6261\u201377. https:\/\/doi.org\/10.7150\/thno.42523.","journal-title":"Theranostics"},{"issue":"1","key":"458_CR103","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41467-017-02287-5","volume":"8","author":"M Kitagawa","year":"2017","unstructured":"Kitagawa M, Liao PJ, Lee KH, Wong J, Shang SC, Minami N, et al. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality. Nat Commun. 2017;8(1):2200. https:\/\/doi.org\/10.1038\/s41467-017-02287-5.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR104","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41467-021-21784-2","volume":"12","author":"M Khaliq","year":"2021","unstructured":"Khaliq M, Manikkam M, Martinez ED, Fallahi-Sichani M. Epigenetic modulation reveals differentiation state specificity of oncogene addiction. Nat Commun. 2021;12(1):1536. https:\/\/doi.org\/10.1038\/s41467-021-21784-2.","journal-title":"Nat Commun"},{"key":"458_CR105","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","volume":"59","author":"Q Yang","year":"2019","unstructured":"Yang Q, Jiang W, Hou P. Emerging role of PI3K\/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112\u201324. https:\/\/doi.org\/10.1016\/j.semcancer.2019.04.001.","journal-title":"Semin Cancer Biol"},{"key":"458_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2025.139088","volume":"495","author":"C Wang","year":"2025","unstructured":"Wang C, Lin J, Deng J, Li X, Zhai J, Yang Y, et al. 6PPD and 6PPDQ exposure promote the proliferation and migration of non-small cell lung cancer cells through PTEN dysfunction and ARG2-mediated metabolic reprogramming. J Hazard Mater. 2025;495:139088. https:\/\/doi.org\/10.1016\/j.jhazmat.2025.139088.","journal-title":"J Hazard Mater"},{"issue":"7781","key":"458_CR107","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-019-1668-3","volume":"575","author":"WA Flavahan","year":"2019","unstructured":"Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229\u201333. https:\/\/doi.org\/10.1038\/s41586-019-1668-3.","journal-title":"Nature"},{"issue":"11","key":"458_CR108","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41556-021-00781-z","volume":"23","author":"Y Li","year":"2021","unstructured":"Li Y, Qiu X, Wang X, Liu H, Geck RC, Tewari AK, et al. FGFR-inhibitor-mediated dismissal of SWI\/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. Nat Cell Biol. 2021;23(11):1187\u201398. https:\/\/doi.org\/10.1038\/s41556-021-00781-z.","journal-title":"Nat Cell Biol"},{"issue":"23","key":"458_CR109","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1158\/0008-5472.Can-17-0899","volume":"77","author":"R Adelaiye-Ogala","year":"2017","unstructured":"Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, et al. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Res. 2017;77(23):6651\u201366. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0899.","journal-title":"Cancer Res"},{"issue":"3","key":"458_CR110","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.Cd-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017;7(3):302\u201321. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0653.","journal-title":"Cancer Discov"},{"issue":"1","key":"458_CR111","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1038\/s41467-020-19704-x","volume":"11","author":"Y Bao","year":"2020","unstructured":"Bao Y, Oguz G, Lee WC, Lee PL, Ghosh K, Li J, et al. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy. Nat Commun. 2020;11(1):5878. https:\/\/doi.org\/10.1038\/s41467-020-19704-x.","journal-title":"Nat Commun"},{"key":"458_CR112","doi-asserted-by":"publisher","unstructured":"Liu S, Zou Q, Chen JP, Yao X, Guan P, Liang W et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. J Clin Invest. 2021;131(20). https:\/\/doi.org\/10.1172\/jci145035.","DOI":"10.1172\/jci145035"},{"issue":"1","key":"458_CR113","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1038\/s41467-024-47957-3","volume":"15","author":"G Rosenberger","year":"2024","unstructured":"Rosenberger G, Li W, Turunen M, He J, Subramaniam PS, Pampou S, et al. Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis. Nat Commun. 2024;15(1):3909. https:\/\/doi.org\/10.1038\/s41467-024-47957-3.","journal-title":"Nat Commun"},{"key":"458_CR114","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev-pharmtox-010617-052954","volume":"58","author":"SP Angus","year":"2018","unstructured":"Angus SP, Zawistowski JS, Johnson GL. Epigenetic mechanisms regulating adaptive responses to targeted kinase inhibitors in cancer. Annu Rev Pharmacol Toxicol. 2018;58:209\u201329. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010617-052954.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"458_CR115","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trecan.2025.02.001","volume":"11","author":"TS Wilson","year":"2025","unstructured":"Wilson TS, Scaffidi P. Compromised epigenetic robustness in cancer: fueling evolution, exposing weakness. Trends Cancer. 2025;11(6):575\u201390. https:\/\/doi.org\/10.1016\/j.trecan.2025.02.001.","journal-title":"Trends Cancer"},{"key":"458_CR116","doi-asserted-by":"publisher","unstructured":"Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin Cancer Res. 2020;26(7):1633\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3523.","DOI":"10.1158\/1078-0432.Ccr-19-3523"},{"issue":"43","key":"458_CR117","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1038\/s41388-022-02465-w","volume":"41","author":"S Ogden","year":"2022","unstructured":"Ogden S, Carys K, Ahmed I, Bruce J, Sharrocks AD. Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition. Oncogene. 2022;41(43):4808\u201322. https:\/\/doi.org\/10.1038\/s41388-022-02465-w.","journal-title":"Oncogene"},{"issue":"20","key":"458_CR118","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/bph.13961","volume":"174","author":"W Yu","year":"2017","unstructured":"Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, et al. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Br J Pharmacol. 2017;174(20):3608\u201322. https:\/\/doi.org\/10.1111\/bph.13961.","journal-title":"Br J Pharmacol"},{"key":"458_CR119","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2020.09.003","volume":"495","author":"C Quan","year":"2020","unstructured":"Quan C, Chen Y, Wang X, Yang D, Wang Q, Huang Y, et al. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Lett. 2020;495:41\u201352. https:\/\/doi.org\/10.1016\/j.canlet.2020.09.003.","journal-title":"Cancer Lett"},{"issue":"4","key":"458_CR120","doi-asserted-by":"publisher","first-page":"974","DOI":"10.7150\/thno.17830","volume":"7","author":"YC Xu","year":"2017","unstructured":"Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, et al. Integration of receptor tyrosine kinases determines sensitivity to PI3K\u03b1-selective inhibitors in breast cancer. Theranostics. 2017;7(4):974\u201386. https:\/\/doi.org\/10.7150\/thno.17830.","journal-title":"Theranostics"},{"issue":"5","key":"458_CR121","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41401-022-01015-0","volume":"44","author":"WL Qi","year":"2023","unstructured":"Qi WL, Li HY, Wang Y, Xu L, Deng JT, Zhang X, et al. Targeting PI3K\u03b1 overcomes resistance to KRas(G12C) inhibitors mediated by activation of EGFR and\/or IGF1R. Acta Pharmacol Sin. 2023;44(5):1083\u201394. https:\/\/doi.org\/10.1038\/s41401-022-01015-0.","journal-title":"Acta Pharmacol Sin"},{"key":"458_CR122","doi-asserted-by":"publisher","unstructured":"Morozov VM, Riva A, Sarwar S, Kim WJ, Li J, Zhou L et al. HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR\/BRD4 complex assembly at enhancers. Nucleic Acids Res. 2023;51(19):10194\u2013217. https:\/\/doi.org\/10.1093\/nar\/gkad700.","DOI":"10.1093\/nar\/gkad700"},{"issue":"11","key":"458_CR123","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2967\/jnumed.117.206730","volume":"59","author":"Z Han","year":"2018","unstructured":"Han Z, Xiao Y, Wang K, Yan J, Xiao Z, Fang F, et al. Development of a SPECT tracer to image c-Met expression in a xenograft model of non-small cell lung cancer. J Nucl Med. 2018;59(11):1686\u201391. https:\/\/doi.org\/10.2967\/jnumed.117.206730.","journal-title":"J Nucl Med"},{"issue":"2","key":"458_CR124","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","volume":"380","author":"P Shi","year":"2016","unstructured":"Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016;380(2):494\u2013504. https:\/\/doi.org\/10.1016\/j.canlet.2016.07.021.","journal-title":"Cancer Lett"},{"issue":"3","key":"458_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104321","volume":"30","author":"X Yao","year":"2025","unstructured":"Yao X, Gao C, Sun C, Chen ZS, Zhuang J. Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies. Drug Discov Today. 2025;30(3):104321. https:\/\/doi.org\/10.1016\/j.drudis.2025.104321.","journal-title":"Drug Discov Today"},{"issue":"24","key":"458_CR126","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1158\/0008-5472.Can-21-3605","volume":"81","author":"JS Bergholz","year":"2021","unstructured":"Bergholz JS, Zhao JJ. How compensatory mechanisms and adaptive rewiring have shaped our understanding of therapeutic resistance in cancer. Cancer Res. 2021;81(24):6074\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-3605.","journal-title":"Cancer Res"},{"issue":"1","key":"458_CR127","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41467-020-14324-x","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Luo M, Zhang K, Zhang J, Gao T, Connell DO, et al. Nedd4 ubiquitylates VDAC2\/3 to suppress erastin-induced ferroptosis in melanoma. Nat Commun. 2020;11(1):433. https:\/\/doi.org\/10.1038\/s41467-020-14324-x.","journal-title":"Nat Commun"},{"issue":"10","key":"458_CR128","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","volume":"27","author":"K Xu","year":"2019","unstructured":"Xu K, Zhan Y, Yuan Z, Qiu Y, Wang H, Fan G, et al. Hypoxia induces drug resistance in colorectal cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 feedback loop. Mol Ther. 2019;27(10):1810\u201324. https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.017.","journal-title":"Mol Ther"},{"issue":"8","key":"458_CR129","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/gutjnl-2021-325405","volume":"71","author":"S Revia","year":"2022","unstructured":"Revia S, Seretny A, Wendler L, Banito A, Eckert C, Breuer K, et al. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut. 2022;71(8):1613\u201328. https:\/\/doi.org\/10.1136\/gutjnl-2021-325405.","journal-title":"Gut"},{"issue":"6","key":"458_CR130","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/gutjnl-2019-319126","volume":"69","author":"SO Kleeman","year":"2020","unstructured":"Kleeman SO, Koelzer VH, Jones HJ, Vazquez EG, Davis H, East JE, et al. Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut. 2020;69(6):1092\u2013103. https:\/\/doi.org\/10.1136\/gutjnl-2019-319126.","journal-title":"Gut"},{"issue":"18","key":"458_CR131","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1158\/0008-5472.Can-16-0123","volume":"76","author":"S Manole","year":"2016","unstructured":"Manole S, Richards EJ, Meyer AS. JNK pathway activation modulates acquired resistance to EGFR\/HER2-targeted therapies. Cancer Res. 2016;76(18):5219\u201328. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-0123.","journal-title":"Cancer Res"},{"issue":"17","key":"458_CR132","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1158\/0008-5472.Can-15-3107","volume":"76","author":"E Pupo","year":"2016","unstructured":"Pupo E, Ducano N, Lupo B, Vigna E, Avanzato D, Perera T, et al. Rebound effects caused by withdrawal of MET kinase inhibitor are quenched by a MET therapeutic antibody. Cancer Res. 2016;76(17):5019\u201329. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-3107.","journal-title":"Cancer Res"},{"issue":"30","key":"458_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400603","volume":"11","author":"N Liu","year":"2024","unstructured":"Liu N, Zheng X, Yan J, Jiang A, Yao Y, He W. Reversing MET-mediated resistance in oncogene-driven NSCLC by MET-activated Wnt condensative prodrug. Adv Sci (Weinh). 2024;11(30):e2400603. https:\/\/doi.org\/10.1002\/advs.202400603.","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"458_CR134","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1158\/2159-8290.Cd-21-0282","volume":"12","author":"DB Burkhardt","year":"2022","unstructured":"Burkhardt DB, San Juan BP, Lock JG, Krishnaswamy S, Chaffer CL. Mapping phenotypic plasticity upon the cancer cell state landscape using manifold learning. Cancer Discov. 2022;12(8):1847\u201359. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0282.","journal-title":"Cancer Discov"},{"issue":"8","key":"458_CR135","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.Cd-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA. The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov. 2023;13(8):1771\u201388. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0225.","journal-title":"Cancer Discov"},{"issue":"8","key":"458_CR136","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2023","unstructured":"P\u00e9rez-Gonz\u00e1lez A, B\u00e9vant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4(8):1063\u201382. https:\/\/doi.org\/10.1038\/s43018-023-00595-y.","journal-title":"Nat Cancer"},{"issue":"6","key":"458_CR137","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41388-020-01591-7","volume":"40","author":"CJ Bergin","year":"2021","unstructured":"Bergin CJ, Zouggar A, Haebe JR, Masibag AN, Desrochers FM, Reilley SY, et al. G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer. Oncogene. 2021;40(6):1191\u2013202. https:\/\/doi.org\/10.1038\/s41388-020-01591-7.","journal-title":"Oncogene"},{"issue":"1","key":"458_CR138","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-017-0596-9","volume":"16","author":"TB Toh","year":"2017","unstructured":"Toh TB, Lim JJ, Chow EK. Epigenetics in cancer stem cells. Mol Cancer. 2017;16(1):29. https:\/\/doi.org\/10.1186\/s12943-017-0596-9.","journal-title":"Mol Cancer"},{"key":"458_CR139","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.semcancer.2021.06.001","volume":"85","author":"Y Song","year":"2022","unstructured":"Song Y, Pan S, Li K, Chen X, Wang ZP, Zhu X. Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers. Semin Cancer Biol. 2022;85:219\u201333. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.001.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"458_CR140","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","volume":"170","author":"L Cimmino","year":"2017","unstructured":"Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170(6):1079-95.e20. https:\/\/doi.org\/10.1016\/j.cell.2017.07.032.","journal-title":"Cell"},{"issue":"7","key":"458_CR141","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-11-684225","volume":"128","author":"RE Rau","year":"2016","unstructured":"Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016;128(7):971\u201381. https:\/\/doi.org\/10.1182\/blood-2015-11-684225.","journal-title":"Blood"},{"key":"458_CR142","doi-asserted-by":"publisher","unstructured":"Kumar VE, Nambiar R, De Souza C, Nguyen A, Chien J, Lam KS. Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells. 2022;11(9). https:\/\/doi.org\/10.3390\/cells11091403.","DOI":"10.3390\/cells11091403"},{"issue":"6","key":"458_CR143","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.7150\/thno.83353","volume":"13","author":"B Li","year":"2023","unstructured":"Li B, Xia Y, Mei S, Ye Z, Song B, Yan X, et al. Histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in sepsis-induced AKI. Theranostics. 2023;13(6):1860\u201375. https:\/\/doi.org\/10.7150\/thno.83353.","journal-title":"Theranostics"},{"issue":"19","key":"458_CR144","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1158\/0008-5472.Can-23-4054","volume":"84","author":"ME Gonzalez","year":"2024","unstructured":"Gonzalez ME, Brophy B, Eido A, Leonetti AE, Djomehri SI, Augimeri G, et al. CCN6 suppresses metaplastic breast carcinoma by antagonizing Wnt\/\u03b2-catenin signaling to inhibit EZH2-driven EMT. Cancer Res. 2024;84(19):3235\u201349. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-4054.","journal-title":"Cancer Res"},{"issue":"11","key":"458_CR145","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.Can-19-3018","volume":"80","author":"N Moshkovich","year":"2020","unstructured":"Moshkovich N, Ochoa HJ, Tang B, Yang HH, Yang Y, Huang J, et al. Peptidylarginine deiminase IV regulates breast cancer stem cells via a novel tumor cell-autonomous suppressor role. Cancer Res. 2020;80(11):2125\u201337. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-3018.","journal-title":"Cancer Res"},{"issue":"1","key":"458_CR146","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12929-016-0296-6","volume":"23","author":"CC Hsu","year":"2016","unstructured":"Hsu CC, Chang WC, Hsu TI, Liu JJ, Yeh SH, Wang JY, et al. Suberoylanilide hydroxamic acid represses glioma stem-like cells. J Biomed Sci. 2016;23(1):81. https:\/\/doi.org\/10.1186\/s12929-016-0296-6.","journal-title":"J Biomed Sci"},{"issue":"9","key":"458_CR147","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1172\/jci138577","volume":"130","author":"H Lu","year":"2020","unstructured":"Lu H, Xie Y, Tran L, Lan J, Yang Y, Murugan NL, et al. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. J Clin Invest. 2020;130(9):4607\u201323. https:\/\/doi.org\/10.1172\/jci138577.","journal-title":"J Clin Invest"},{"key":"458_CR148","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016683","author":"S Biswas","year":"2025","unstructured":"Biswas S, Zahran Z, Gu X, Cardone L, Marti R, Mouannes N, et al. Combining drugs that bypass p53 to treat TP53-mutated leukemias. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025016683.","journal-title":"Blood Adv"},{"issue":"40","key":"458_CR149","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.1038\/s41388-019-0905-4","volume":"38","author":"S Beyes","year":"2019","unstructured":"Beyes S, Andrieux G, Schrempp M, Aicher D, Wenzel J, Ant\u00f3n-Garc\u00eda P, et al. Genome-wide mapping of DNA-binding sites identifies stemness-related genes as directly repressed targets of SNAIL1 in colorectal cancer cells. Oncogene. 2019;38(40):6647\u201361. https:\/\/doi.org\/10.1038\/s41388-019-0905-4.","journal-title":"Oncogene"},{"issue":"1","key":"458_CR150","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41467-023-36505-0","volume":"14","author":"MC Paul","year":"2023","unstructured":"Paul MC, Schneeweis C, Falcomat\u00e0 C, Shan C, Rossmeisl D, Koutsouli S, et al. Non-canonical functions of SNAIL drive context-specific cancer progression. Nat Commun. 2023;14(1):1201. https:\/\/doi.org\/10.1038\/s41467-023-36505-0.","journal-title":"Nat Commun"},{"issue":"4","key":"458_CR151","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/blood-2016-05-714659","volume":"129","author":"J Li","year":"2017","unstructured":"Li J, Riedt T, Goossens S, Carrillo Garc\u00eda C, Szczepanski S, Brandes M, et al. The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling. Blood. 2017;129(4):460\u201372. https:\/\/doi.org\/10.1182\/blood-2016-05-714659.","journal-title":"Blood"},{"key":"458_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.068","volume":"420","author":"W Xu","year":"2018","unstructured":"Xu W, Liu H, Liu ZG, Wang HS, Zhang F, Wang H, et al. Histone deacetylase inhibitors upregulate Snail via Smad2\/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells. Cancer Lett. 2018;420:1\u201313. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.068.","journal-title":"Cancer Lett"},{"issue":"1","key":"458_CR153","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13046-019-1220-1","volume":"38","author":"J Chen","year":"2019","unstructured":"Chen J, Zhu H, Liu Q, Ning D, Zhang Z, Zhang L, et al. DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGF\u03b21 signaling and is associated with poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):273. https:\/\/doi.org\/10.1186\/s13046-019-1220-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"458_CR154","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1016\/j.ijbiomac.2020.08.221","volume":"164","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wu T, Wang Y, Zhao X, Zhao B, Zhao X, et al. The R251Q mutation of LSD1 promotes invasion and migration of luminal breast cancer cells. Int J Biol Macromol. 2020;164:4000\u20139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.08.221.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"458_CR155","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41580-022-00518-2","volume":"24","author":"TA Macrae","year":"2023","unstructured":"Macrae TA, Fothergill-Robinson J, Ramalho-Santos M. Regulation, functions and transmission of bivalent chromatin during mammalian development. Nat Rev Mol Cell Biol. 2023;24(1):6\u201326. https:\/\/doi.org\/10.1038\/s41580-022-00518-2.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"458_CR156","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/2159-8290.Cd-20-1863","volume":"11","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;11(12):3028\u201347. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1863.","journal-title":"Cancer Discov"},{"issue":"9","key":"458_CR157","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/2159-8290.Cd-24-1866","volume":"15","author":"I Vathiotis","year":"2025","unstructured":"Vathiotis I, Banerjee A, Sen U, Saalfeld FC, Halder D, Charpidou A, et al. Histologic transformation in cancer: the path for clinical translation. Cancer Discov. 2025;15(9):1783\u201393. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-1866.","journal-title":"Cancer Discov"},{"issue":"1","key":"458_CR158","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun. 2024;15(1):6779. https:\/\/doi.org\/10.1038\/s41467-024-51156-5.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR159","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41467-019-09309-4","volume":"10","author":"E Lima-Fernandes","year":"2019","unstructured":"Lima-Fernandes E, Murison A, da Silva MT, Wang Y, Ma A, Leung C, et al. Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. Nat Commun. 2019;10(1):1436. https:\/\/doi.org\/10.1038\/s41467-019-09309-4.","journal-title":"Nat Commun"},{"issue":"8","key":"458_CR160","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1158\/0008-5472.Can-24-0274","volume":"84","author":"PH Rumde","year":"2024","unstructured":"Rumde PH, Burns TF. A path to persistence after EGFR inhibition. Cancer Res. 2024;84(8):1188\u201390. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-0274.","journal-title":"Cancer Res"},{"issue":"3","key":"458_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101471","volume":"5","author":"M Chen","year":"2024","unstructured":"Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep Med. 2024;5(3):101471. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101471.","journal-title":"Cell Rep Med"},{"issue":"2","key":"458_CR162","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","volume":"32","author":"GD Guler","year":"2017","unstructured":"Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, et al. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell. 2017;32(2):221-37.e13. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.002.","journal-title":"Cancer Cell"},{"issue":"4","key":"458_CR163","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41588-022-01047-6","volume":"54","author":"J Marsolier","year":"2022","unstructured":"Marsolier J, Prompsy P, Durand A, Lyne AM, Landragin C, Trouchet A, et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat Genet. 2022;54(4):459\u201368. https:\/\/doi.org\/10.1038\/s41588-022-01047-6.","journal-title":"Nat Genet"},{"key":"458_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.122645","volume":"346","author":"Q Tang","year":"2024","unstructured":"Tang Q, Leng S, Tan Y, Cheng H, Liu Q, Wang Z, et al. Chitosan\/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo\/immuno-resistance in unresectable metastatic melanoma. Carbohydr Polym. 2024;346:122645. https:\/\/doi.org\/10.1016\/j.carbpol.2024.122645.","journal-title":"Carbohydr Polym"},{"issue":"7","key":"458_CR165","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova M, Gehling VS, Gustafson A, Arora S, Tindell CA, Wilson C, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol. 2016;12(7):531\u20138. https:\/\/doi.org\/10.1038\/nchembio.2085.","journal-title":"Nat Chem Biol"},{"key":"458_CR166","doi-asserted-by":"publisher","unstructured":"Portelinha A, Wang S, Parsa S, Jiang M, Gorelick AN, Mohanty S et al. SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma. J Exp Med. 2024;221(10). https:\/\/doi.org\/10.1084\/jem.20231143.","DOI":"10.1084\/jem.20231143"},{"issue":"8","key":"458_CR167","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.7150\/thno.39944","volume":"10","author":"L Chen","year":"2020","unstructured":"Chen L, Wang Z, Xu Q, Liu Y, Chen L, Guo S, et al. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma. Theranostics. 2020;10(8):3562\u201378. https:\/\/doi.org\/10.7150\/thno.39944.","journal-title":"Theranostics"},{"issue":"1","key":"458_CR168","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40880-018-0302-3","volume":"38","author":"YP Wang","year":"2018","unstructured":"Wang YP, Lei QY. Metabolic recoding of epigenetics in cancer. Cancer Commun (Lond). 2018;38(1):25. https:\/\/doi.org\/10.1186\/s40880-018-0302-3.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"458_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188906","volume":"1878","author":"P Dhakne","year":"2023","unstructured":"Dhakne P, Pillai M, Mishra S, Chatterjee B, Tekade RK, Sengupta P. Refinement of safety and efficacy of anti-cancer chemotherapeutics by tailoring their site-specific intracellular bioavailability through transporter modulation. Biochim Biophys Acta Rev Cancer. 2023;1878(4):188906. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188906.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"458_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.02.010","volume":"135","author":"ML Rives","year":"2017","unstructured":"Rives ML, Javitch JA, Wickenden AD. Potentiating SLC transporter activity: emerging drug discovery opportunities. Biochem Pharmacol. 2017;135:1\u201311. https:\/\/doi.org\/10.1016\/j.bcp.2017.02.010.","journal-title":"Biochem Pharmacol"},{"key":"458_CR171","doi-asserted-by":"publisher","unstructured":"Zappe K, Cichna-Markl M. Aberrant DNA methylation of ABC transporters in cancer. Cells. 2020;9(10). https:\/\/doi.org\/10.3390\/cells9102281.","DOI":"10.3390\/cells9102281"},{"key":"458_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115930","volume":"170","author":"E Cerovska","year":"2024","unstructured":"Cerovska E, Salek C, Kundrat D, Sestakova S, Pesek A, Brozinova I, et al. ABC transporters are predictors of treatment failure in acute myeloid leukaemia. Biomed Pharmacother. 2024;170:115930. https:\/\/doi.org\/10.1016\/j.biopha.2023.115930.","journal-title":"Biomed Pharmacother"},{"issue":"25","key":"458_CR173","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1093\/eurheartj\/ehaf130","volume":"46","author":"B Tu","year":"2025","unstructured":"Tu B, Song K, Zhou ZY, Lin LC, Liu ZY, Sun H, et al. SLC31A1 loss depletes mitochondrial copper and promotes cardiac fibrosis. Eur Heart J. 2025;46(25):2458\u201374. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf130.","journal-title":"Eur Heart J"},{"issue":"5","key":"458_CR174","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.apsb.2019.01.002","volume":"9","author":"L Chen","year":"2019","unstructured":"Chen L, Chen L, Qin Z, Lei J, Ye S, Zeng K, et al. Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2. Acta Pharm Sin B. 2019;9(5):1008\u201320. https:\/\/doi.org\/10.1016\/j.apsb.2019.01.002.","journal-title":"Acta Pharm Sin B"},{"issue":"18","key":"458_CR175","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1038\/s41388-018-0671-8","volume":"38","author":"M Li","year":"2019","unstructured":"Li M, Tang Y, Li Q, Xiao M, Yang Y, Wang Y. Mono-ADP-ribosylation of H3R117 traps 5mC hydroxylase TET1 to impair demethylation of tumor suppressor gene TFPI2. Oncogene. 2019;38(18):3488\u2013503. https:\/\/doi.org\/10.1038\/s41388-018-0671-8.","journal-title":"Oncogene"},{"issue":"6","key":"458_CR176","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1124\/pharmrev.124.001173","volume":"76","author":"FP Guengerich","year":"2024","unstructured":"Guengerich FP. Roles of individual human cytochrome P450 enzymes in drug metabolism. Pharmacol Rev. 2024;76(6):1104\u201332. https:\/\/doi.org\/10.1124\/pharmrev.124.001173.","journal-title":"Pharmacol Rev"},{"issue":"W1","key":"458_CR177","doi-asserted-by":"publisher","first-page":"W580","DOI":"10.1093\/nar\/gkaa166","volume":"48","author":"P Banerjee","year":"2020","unstructured":"Banerjee P, Dunkel M, Kemmler E, Preissner R. SuperCYPsPred-a web server for the prediction of cytochrome activity. Nucleic Acids Res. 2020;48(W1):W580\u20135. https:\/\/doi.org\/10.1093\/nar\/gkaa166.","journal-title":"Nucleic Acids Res"},{"key":"458_CR178","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bcp.2016.06.007","volume":"113","author":"Y Jin","year":"2016","unstructured":"Jin Y, Yu D, Tolleson WH, Knox B, Wang Y, Chen S, et al. MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. Biochem Pharmacol. 2016;113:88\u201396. https:\/\/doi.org\/10.1016\/j.bcp.2016.06.007.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"458_CR179","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.apsb.2016.12.006","volume":"7","author":"AM Yu","year":"2017","unstructured":"Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, et al. Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21(st) International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B. 2017;7(2):241\u20138. https:\/\/doi.org\/10.1016\/j.apsb.2016.12.006.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"458_CR180","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s11357-020-00181-5","volume":"42","author":"MM Kronfol","year":"2020","unstructured":"Kronfol MM, Jahr FM, Dozmorov MG, Phansalkar PS, Xie LY, Aberg KA, et al. DNA methylation and histone acetylation changes to cytochrome P450 2E1 regulation in normal aging and impact on rates of drug metabolism in the liver. Geroscience. 2020;42(3):819\u201332. https:\/\/doi.org\/10.1007\/s11357-020-00181-5.","journal-title":"Geroscience"},{"issue":"18","key":"458_CR181","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.Can-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3962.","journal-title":"Cancer Res"},{"issue":"1","key":"458_CR182","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12943-021-01313-x","volume":"20","author":"S Mohapatra","year":"2021","unstructured":"Mohapatra S, Pioppini C, Ozpolat B, Calin GA. Non-coding RNAs regulation of macrophage polarization in cancer. Mol Cancer. 2021;20(1):24. https:\/\/doi.org\/10.1186\/s12943-021-01313-x.","journal-title":"Mol Cancer"},{"issue":"14","key":"458_CR183","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.Can-22-1270","volume":"83","author":"X Zheng","year":"2023","unstructured":"Zheng X, Sarode P, Weigert A, Turkowski K, Chelladurai P, G\u00fcnther S, et al. The HDAC2-SP1 axis orchestrates protumor macrophage polarization. Cancer Res. 2023;83(14):2345\u201357. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-1270.","journal-title":"Cancer Res"},{"issue":"14","key":"458_CR184","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.7150\/thno.51864","volume":"11","author":"J Xun","year":"2021","unstructured":"Xun J, Du L, Gao R, Shen L, Wang D, Kang L, et al. Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B. Theranostics. 2021;11(14):6847\u201359. https:\/\/doi.org\/10.7150\/thno.51864.","journal-title":"Theranostics"},{"issue":"1","key":"458_CR185","doi-asserted-by":"publisher","first-page":"1986665","DOI":"10.1080\/19490976.2021.1986665","volume":"13","author":"S Rana","year":"2021","unstructured":"Rana S, Maurya S, Mohapatra G, Singh S, Babar R, Chandrasekhar H, et al. Activation of epigenetic regulator KDM6B by Salmonella Typhimurium enables chronic infections. Gut Microbes. 2021;13(1):1986665. https:\/\/doi.org\/10.1080\/19490976.2021.1986665.","journal-title":"Gut Microbes"},{"key":"458_CR186","doi-asserted-by":"publisher","unstructured":"Chen S, Chen Z, Zhou B, Chen Y, Huang Y, Cao J et al. PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy. J Immunother Cancer. 2025;13(4). https:\/\/doi.org\/10.1136\/jitc-2024-011299.","DOI":"10.1136\/jitc-2024-011299"},{"issue":"11","key":"458_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101804","volume":"5","author":"T Tay","year":"2024","unstructured":"Tay T, Bommakanti G, Jaensch E, Gorthi A, Karapa Reddy I, Hu Y, et al. Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay. Cell Rep Med. 2024;5(11):101804. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101804.","journal-title":"Cell Rep Med"},{"issue":"7764","key":"458_CR188","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott AC, D\u00fcndar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270\u20134. https:\/\/doi.org\/10.1038\/s41586-019-1324-y.","journal-title":"Nature"},{"issue":"4","key":"458_CR189","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jhep.2019.05.015","volume":"71","author":"X Wang","year":"2019","unstructured":"Wang X, He Q, Shen H, Xia A, Tian W, Yu W, et al. TOX promotes the exhaustion of antitumor CD8(+) T cells by preventing PD1 degradation in hepatocellular carcinoma. J Hepatol. 2019;71(4):731\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.015.","journal-title":"J Hepatol"},{"issue":"8","key":"458_CR190","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-021-00979-1","volume":"22","author":"KB Yates","year":"2021","unstructured":"Yates KB, Tonnerre P, Martin GE, Gerdemann U, Al Abosy R, Comstock DE, et al. Epigenetic scars of CD8(+) T cell exhaustion persist after cure of chronic infection in humans. Nat Immunol. 2021;22(8):1020\u20139. https:\/\/doi.org\/10.1038\/s41590-021-00979-1.","journal-title":"Nat Immunol"},{"issue":"1","key":"458_CR191","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13073-020-00722-9","volume":"12","author":"K Kim","year":"2020","unstructured":"Kim K, Park S, Park SY, Kim G, Park SM, Cho JW, et al. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. Genome Med. 2020;12(1):22. https:\/\/doi.org\/10.1186\/s13073-020-00722-9.","journal-title":"Genome Med"},{"issue":"1","key":"458_CR192","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12951-024-02452-1","volume":"22","author":"X Xue","year":"2024","unstructured":"Xue X, Wang X, Pang M, Yu L, Qian J, Li X, et al. An exosomal strategy for targeting cancer-associated fibroblasts mediated tumors desmoplastic microenvironments. J Nanobiotechnology. 2024;22(1):196. https:\/\/doi.org\/10.1186\/s12951-024-02452-1.","journal-title":"J Nanobiotechnology"},{"issue":"12","key":"458_CR193","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804. https:\/\/doi.org\/10.1038\/s41571-021-00546-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"458_CR194","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gutjnl-2018-317645","volume":"69","author":"M Maeda","year":"2020","unstructured":"Maeda M, Takeshima H, Iida N, Hattori N, Yamashita S, Moro H, et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. Gut. 2020;69(2):243\u201351. https:\/\/doi.org\/10.1136\/gutjnl-2018-317645.","journal-title":"Gut"},{"key":"458_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119975","volume":"247","author":"H Saini","year":"2020","unstructured":"Saini H, Rahmani Eliato K, Veldhuizen J, Zare A, Allam M, Silva C, et al. The role of tumor-stroma interactions on desmoplasia and tumorigenicity within a microengineered 3D platform. Biomaterials. 2020;247:119975. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119975.","journal-title":"Biomaterials"},{"issue":"16","key":"458_CR196","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/0008-5472.Can-21-4313","volume":"82","author":"J Yi","year":"2022","unstructured":"Yi J, Kim B, Shi X, Zhan X, Lu QR, Xuan Z, et al. PRC2 heterogeneity drives tumor growth in medulloblastoma. Cancer Res. 2022;82(16):2874\u201386. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-4313.","journal-title":"Cancer Res"},{"issue":"1","key":"458_CR197","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41568-024-00757-9","volume":"25","author":"M Laisn\u00e9","year":"2025","unstructured":"Laisn\u00e9 M, Lupien M, Vallot C. Epigenomic heterogeneity as a source of tumour evolution. Nat Rev Cancer. 2025;25(1):7\u201326. https:\/\/doi.org\/10.1038\/s41568-024-00757-9.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"458_CR198","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1038\/s41467-023-43417-6","volume":"14","author":"EM Bertucci-Richter","year":"2023","unstructured":"Bertucci-Richter EM, Parrott BB. The rate of epigenetic drift scales with maximum lifespan across mammals. Nat Commun. 2023;14(1):7731. https:\/\/doi.org\/10.1038\/s41467-023-43417-6.","journal-title":"Nat Commun"},{"key":"458_CR199","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcancer.2018.01.010","volume":"51","author":"Y Assenov","year":"2018","unstructured":"Assenov Y, Brocks D, Gerh\u00e4user C. Intratumor heterogeneity in epigenetic patterns. Semin Cancer Biol. 2018;51:12\u201321. https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.010.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"458_CR200","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tcb.2019.03.003","volume":"29","author":"K Hinohara","year":"2019","unstructured":"Hinohara K, Polyak K. Intratumoral heterogeneity: more than just mutations. Trends Cell Biol. 2019;29(7):569\u201379. https:\/\/doi.org\/10.1016\/j.tcb.2019.03.003.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"458_CR201","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.Cd-13-0349","volume":"4","author":"CC Oakes","year":"2014","unstructured":"Oakes CC, Claus R, Gu L, Assenov Y, H\u00fcllein J, Zucknick M, et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014;4(3):348\u201361. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0349.","journal-title":"Cancer Discov"},{"issue":"6","key":"458_CR202","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s13238-020-00819-2","volume":"12","author":"Y Feng","year":"2021","unstructured":"Feng Y, Liu X, Pauklin S. 3D chromatin architecture and epigenetic regulation in cancer stem cells. Protein Cell. 2021;12(6):440\u201354. https:\/\/doi.org\/10.1007\/s13238-020-00819-2.","journal-title":"Protein Cell"},{"issue":"1","key":"458_CR203","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","volume":"24","author":"Y Pan","year":"2025","unstructured":"Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24(1):52. https:\/\/doi.org\/10.1186\/s12943-025-02265-2.","journal-title":"Mol Cancer"},{"issue":"1","key":"458_CR204","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-025-58370-9","volume":"16","author":"S Takao","year":"2025","unstructured":"Takao S, Morell V, Uni M, Slavit A, Rha S, Cheng S, et al. Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance. Nat Commun. 2025;16(1):3196. https:\/\/doi.org\/10.1038\/s41467-025-58370-9.","journal-title":"Nat Commun"},{"issue":"16","key":"458_CR205","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.7150\/thno.20725","volume":"7","author":"G Zhou","year":"2017","unstructured":"Zhou G, Latchoumanin O, Bagdesar M, Hebbard L, Duan W, Liddle C, et al. Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics. 2017;7(16):3948\u201361. https:\/\/doi.org\/10.7150\/thno.20725.","journal-title":"Theranostics"},{"issue":"1","key":"458_CR206","doi-asserted-by":"publisher","first-page":"10482","DOI":"10.1038\/s41467-025-65477-6","volume":"16","author":"M Mardamshina","year":"2025","unstructured":"Mardamshina M, Karagach S, Mohan V, Arad G, Necula D, Golani O, et al. Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity. Nat Commun. 2025;16(1):10482. https:\/\/doi.org\/10.1038\/s41467-025-65477-6.","journal-title":"Nat Commun"},{"key":"458_CR207","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2024.06.003","volume":"102\u2013103","author":"R Bhattacharya","year":"2024","unstructured":"Bhattacharya R, Brown JS, Gatenby RA, Ibrahim-Hashim A. A gene for all seasons: the evolutionary consequences of HIF-1 in carcinogenesis, tumor growth and metastasis. Semin Cancer Biol. 2024;102\u2013103:17\u201324. https:\/\/doi.org\/10.1016\/j.semcancer.2024.06.003.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"458_CR208","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41423-020-0505-9","volume":"17","author":"X Pan","year":"2020","unstructured":"Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol. 2020;17(9):940\u201353. https:\/\/doi.org\/10.1038\/s41423-020-0505-9.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"458_CR209","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","volume":"13","author":"C Meiller","year":"2021","unstructured":"Meiller C, Montagne F, Hirsch TZ, Caruso S, de Wolf J, Bayard Q, et al. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Med. 2021;13(1):113. https:\/\/doi.org\/10.1186\/s13073-021-00931-w.","journal-title":"Genome Med"},{"issue":"10","key":"458_CR210","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41591-018-0156-x","volume":"24","author":"J Klughammer","year":"2018","unstructured":"Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med. 2018;24(10):1611\u201324. https:\/\/doi.org\/10.1038\/s41591-018-0156-x.","journal-title":"Nat Med"},{"issue":"3","key":"458_CR211","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tem.2023.11.005","volume":"35","author":"C Mancini","year":"2024","unstructured":"Mancini C, Lori G, Pranzini E, Taddei ML. Metabolic challengers selecting tumor-persistent cells. Trends Endocrinol Metab. 2024;35(3):263\u201376. https:\/\/doi.org\/10.1016\/j.tem.2023.11.005.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"458_CR212","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","volume":"17","author":"B Golding","year":"2018","unstructured":"Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52. https:\/\/doi.org\/10.1186\/s12943-018-0810-4.","journal-title":"Mol Cancer"},{"issue":"14","key":"458_CR213","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1158\/0008-5472.Can-18-3652","volume":"79","author":"C Grassberger","year":"2019","unstructured":"Grassberger C, McClatchy D 3rd, Geng C, Kamran SC, Fintelmann F, Maruvka YE, et al. Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies. Cancer Res. 2019;79(14):3776\u201388. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3652.","journal-title":"Cancer Res"},{"issue":"6","key":"458_CR214","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.trecan.2020.02.016","volume":"6","author":"SMB Nijman","year":"2020","unstructured":"Nijman SMB. Perturbation-driven entropy as a source of cancer cell heterogeneity. Trends Cancer. 2020;6(6):454\u201361. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.016.","journal-title":"Trends Cancer"},{"issue":"22","key":"458_CR215","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/jco.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II triaJ Clin Oncol. 2017;35(22):2490\u20138. https:\/\/doi.org\/10.1200\/jco.2016.71.5904.","journal-title":"J Clin Oncol"},{"issue":"31","key":"458_CR216","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506950","volume":"12","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang X, Yang X, Chen X, Wang Y, Hu J, et al. EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer. Adv Sci (Weinh). 2025;12(31):e06950. https:\/\/doi.org\/10.1002\/advs.202506950.","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"458_CR217","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.Cd-16-0164","volume":"6","author":"H Zhang","year":"2016","unstructured":"Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discov. 2016;6(9):1006\u201321. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0164.","journal-title":"Cancer Discov"},{"issue":"3","key":"458_CR218","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1158\/0008-5472.Can-21-4311","volume":"82","author":"V Adema","year":"2022","unstructured":"Adema V, Colla S. EZH2 inhibitors: the unpacking revolution. Cancer Res. 2022;82(3):359\u201361. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-4311.","journal-title":"Cancer Res"},{"issue":"1","key":"458_CR219","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1038\/s41467-018-07853-z","volume":"9","author":"F Li","year":"2018","unstructured":"Li F, Zeng Z, Xing S, Gullicksrud JA, Shan Q, Choi J, et al. Ezh2 programs T(FH) differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf. Nat Commun. 2018;9(1):5452. https:\/\/doi.org\/10.1038\/s41467-018-07853-z.","journal-title":"Nat Commun"},{"key":"458_CR220","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-25-0433","author":"T Liu","year":"2025","unstructured":"Liu T, Huang S, Li Z, Li J, Sun Q, Wang Q, et al. Transfer of damaged mitochondria from cancer cells to cancer-associated fibroblasts promotes tyrosine kinase inhibitor tolerance in EGFR-mutant lung cancer. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/0008-5472.Can-25-0433.","journal-title":"Cancer Res"},{"issue":"6","key":"458_CR221","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41588-019-0424-9","volume":"51","author":"K Grosselin","year":"2019","unstructured":"Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F, et al. High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019;51(6):1060\u20136. https:\/\/doi.org\/10.1038\/s41588-019-0424-9.","journal-title":"Nat Genet"},{"issue":"19","key":"458_CR222","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood.2023019758","volume":"142","author":"AM Poos","year":"2023","unstructured":"Poos AM, Prokoph N, Przybilla MJ, Mallm JP, Steiger S, Seufert I, et al. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. Blood. 2023;142(19):1633\u201346. https:\/\/doi.org\/10.1182\/blood.2023019758.","journal-title":"Blood"},{"key":"458_CR223","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pharmthera.2016.05.003","volume":"165","author":"A Italiano","year":"2016","unstructured":"Italiano A. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacol Ther. 2016;165:26\u201331. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.05.003.","journal-title":"Pharmacol Ther"},{"key":"458_CR224","doi-asserted-by":"publisher","unstructured":"Gretarsson KH, Abini-Agbomson S, Gloor SL, Weinberg DN, McCuiston JL, Kumary VUS et al. Cancer-associated DNA hypermethylation of Polycomb targets requires DNMT3A dual recognition of histone H2AK119 ubiquitination and the nucleosome acidic patch. Sci Adv. 2024;10(35):eadp0975. https:\/\/doi.org\/10.1126\/sciadv.adp0975.","DOI":"10.1126\/sciadv.adp0975"},{"issue":"1","key":"458_CR225","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1038\/s41467-021-22665-4","volume":"12","author":"W Ren","year":"2021","unstructured":"Ren W, Fan H, Grimm SA, Kim JJ, Li L, Guo Y, et al. DNMT1 reads heterochromatic H4K20me3 to reinforce LINE-1 DNA methylation. Nat Commun. 2021;12(1):2490. https:\/\/doi.org\/10.1038\/s41467-021-22665-4.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR226","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13073-016-0305-0","volume":"8","author":"C Flinders","year":"2016","unstructured":"Flinders C, Lam L, Rubbi L, Ferrari R, Fitz-Gibbon S, Chen PY, et al. Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med. 2016;8(1):54. https:\/\/doi.org\/10.1186\/s13073-016-0305-0.","journal-title":"Genome Med"},{"issue":"1","key":"458_CR227","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10(1):4278. https:\/\/doi.org\/10.1038\/s41467-019-12159-9.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR228","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10(1):219. https:\/\/doi.org\/10.1038\/s41392-025-02266-z.","journal-title":"Signal Transduct Target Ther"},{"key":"458_CR229","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pharmthera.2017.11.002","volume":"184","author":"GD Ginder","year":"2018","unstructured":"Ginder GD, Williams DC Jr. Readers of DNA methylation, the MBD family as potential therapeutic targets. Pharmacol Ther. 2018;184:98\u2013111. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.11.002.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"458_CR230","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/2159-8290.Cd-25-0587","volume":"15","author":"C Huang","year":"2025","unstructured":"Huang C, Gao Y, Chen J, Hong JH, Jiang Y, Chai KXY, et al. Priming with DNMT inhibitors potentiates PD-1 immunotherapy by triggering viral mimicry in relapsed\/refractory NK\/T-cell lymphoma. Cancer Discov. 2025;15(12):2450\u201367. https:\/\/doi.org\/10.1158\/2159-8290.Cd-25-0587.","journal-title":"Cancer Discov"},{"issue":"6","key":"458_CR231","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1172\/jci97924","volume":"128","author":"J Yu","year":"2018","unstructured":"Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018;128(6):2376\u201388. https:\/\/doi.org\/10.1172\/jci97924.","journal-title":"J Clin Invest"},{"issue":"10","key":"458_CR232","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002\u201317.","journal-title":"Nat Cancer"},{"issue":"3","key":"458_CR233","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10555-023-10113-2","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, Sheng Y, Sun X, Wang Y. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer Metastasis Rev. 2023;42(3):891\u2013925. https:\/\/doi.org\/10.1007\/s10555-023-10113-2.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"458_CR234","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1158\/0008-5472.Can-17-1492","volume":"78","author":"F Fang","year":"2018","unstructured":"Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, et al. Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. Cancer Res. 2018;78(3):631\u201344. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1492.","journal-title":"Cancer Res"},{"issue":"12","key":"458_CR235","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ajh.26667","volume":"97","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am J Hematol. 2022;97(12):1616\u201326. https:\/\/doi.org\/10.1002\/ajh.26667.","journal-title":"Am J Hematol"},{"issue":"41","key":"458_CR236","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1038\/s41388-020-01438-1","volume":"39","author":"M Vernier","year":"2020","unstructured":"Vernier M, McGuirk S, Dufour CR, Wan L, Audet-Walsh E, St-Pierre J, et al. Inhibition of DNMT1 and ERR\u03b1 crosstalk suppresses breast cancer via derepression of IRF4. Oncogene. 2020;39(41):6406\u201320. https:\/\/doi.org\/10.1038\/s41388-020-01438-1.","journal-title":"Oncogene"},{"issue":"6","key":"458_CR237","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/med.21437","volume":"37","author":"C Zagni","year":"2017","unstructured":"Zagni C, Floresta G, Monciino G, Rescifina A. The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat. Med Res Rev. 2017;37(6):1373\u2013428. https:\/\/doi.org\/10.1002\/med.21437.","journal-title":"Med Res Rev"},{"issue":"18","key":"458_CR238","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1158\/0008-5472.Can-17-0072","volume":"77","author":"KH Song","year":"2017","unstructured":"Song KH, Choi CH, Lee HJ, Oh SJ, Woo SR, Hong SO, et al. HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells. Cancer Res. 2017;77(18):5039\u201353. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0072.","journal-title":"Cancer Res"},{"issue":"12","key":"458_CR239","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/leu.2017.130","volume":"31","author":"J Long","year":"2017","unstructured":"Long J, Fang WY, Chang L, Gao WH, Shen Y, Jia MY, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017;31(12):2761\u201370. https:\/\/doi.org\/10.1038\/leu.2017.130.","journal-title":"Leukemia"},{"key":"458_CR240","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semcancer.2025.05.008","volume":"113","author":"KKW To","year":"2025","unstructured":"To KKW, Tolu SS, Wang L, Zhang H, Cho WC, Bates SE. HDAC inhibitors: cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury. Semin Cancer Biol. 2025;113:25\u201338. https:\/\/doi.org\/10.1016\/j.semcancer.2025.05.008.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"458_CR241","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, et al. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11(1):111. https:\/\/doi.org\/10.1186\/s13045-018-0654-9.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"458_CR242","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/0008-5472.Can-18-2052","volume":"79","author":"K Fukuda","year":"2019","unstructured":"Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, et al. Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Res. 2019;79(7):1658\u201370. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-2052.","journal-title":"Cancer Res"},{"issue":"9","key":"458_CR243","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/cac2.12180","volume":"41","author":"H Wei","year":"2021","unstructured":"Wei H, Ma W, Lu X, Liu H, Lin K, Wang Y, et al. KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression. Cancer Commun (Lond). 2021;41(9):904\u201320. https:\/\/doi.org\/10.1002\/cac2.12180.","journal-title":"Cancer Commun (Lond)"},{"issue":"17","key":"458_CR244","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.Can-19-3738","volume":"80","author":"D Banik","year":"2020","unstructured":"Banik D, Noonepalle S, Hadley M, Palmer E, Gracia-Hernandez M, Zevallos-Delgado C, et al. HDAC6 Plays a Noncanonical role in the regulation of antitumor immune responses, dissemination, and invasiveness of breast cancer. Cancer Res. 2020;80(17):3649\u201362. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-3738.","journal-title":"Cancer Res"},{"issue":"21","key":"458_CR245","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/0008-5472.Can-19-1302","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, et al. HDAC6 inhibition synergizes with Anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. 2019;79(21):5482\u20139. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-1302.","journal-title":"Cancer Res"},{"key":"458_CR246","doi-asserted-by":"publisher","unstructured":"Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N et al. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. Sci Adv. 2024;10(46):eadp3687. https:\/\/doi.org\/10.1126\/sciadv.adp3687.","DOI":"10.1126\/sciadv.adp3687"},{"issue":"10","key":"458_CR247","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41580-019-0151-1","volume":"20","author":"A Jambhekar","year":"2019","unstructured":"Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 2019;20(10):625\u201341. https:\/\/doi.org\/10.1038\/s41580-019-0151-1.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"458_CR248","doi-asserted-by":"publisher","unstructured":"Gold S, Shilatifard A. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges. J Clin Invest. 2024;134(20). https:\/\/doi.org\/10.1172\/jci183391.","DOI":"10.1172\/jci183391"},{"issue":"1","key":"458_CR249","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"458_CR250","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1158\/0008-5472.Can-20-1259","volume":"80","author":"L Du","year":"2020","unstructured":"Du L, Fakih MG, Rosen ST, Chen Y. SUMOylation of E2F1 regulates expression of EZH2. Cancer Res. 2020;80(19):4212\u201323. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-1259.","journal-title":"Cancer Res"},{"issue":"8","key":"458_CR251","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41375-019-0392-1","volume":"33","author":"L Herviou","year":"2019","unstructured":"Herviou L, Jourdan M, Martinez AM, Cavalli G, Moreaux J. EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation. Leukemia. 2019;33(8):2047\u201360. https:\/\/doi.org\/10.1038\/s41375-019-0392-1.","journal-title":"Leukemia"},{"issue":"11","key":"458_CR252","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.7150\/thno.21966","volume":"8","author":"S Xu","year":"2018","unstructured":"Xu S, Xu Y, Yin M, Zhang S, Liu P, Koroleva M, et al. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics. 2018;8(11):3007\u201321. https:\/\/doi.org\/10.7150\/thno.21966.","journal-title":"Theranostics"},{"issue":"1","key":"458_CR253","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","volume":"12","author":"Y Fang","year":"2019","unstructured":"Fang Y, Liao G, Yu B. LSD1\/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12(1):129. https:\/\/doi.org\/10.1186\/s13045-019-0811-9.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"458_CR254","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1038\/s41467-024-48607-4","volume":"15","author":"F Qiu","year":"2024","unstructured":"Qiu F, Jiang P, Zhang G, An J, Ruan K, Lyu X, et al. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nat Commun. 2024;15(1):4327. https:\/\/doi.org\/10.1038\/s41467-024-48607-4.","journal-title":"Nat Commun"},{"issue":"7","key":"458_CR255","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell. 2020;11(7):472\u201382. https:\/\/doi.org\/10.1007\/s13238-020-00694-x.","journal-title":"Protein Cell"},{"key":"458_CR256","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.semcancer.2020.11.005","volume":"83","author":"B Biersack","year":"2022","unstructured":"Biersack B, Polat S, H\u00f6pfner M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol. 2022;83:472\u201386. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.005.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"458_CR257","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13046-025-03294-x","volume":"44","author":"MK Jakobsen","year":"2025","unstructured":"Jakobsen MK, Traynor S, Nielsen AY, Dahl C, Staehr M, Jakobsen ST, et al. Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition. J Exp Clin Cancer Res. 2025;44(1):21. https:\/\/doi.org\/10.1186\/s13046-025-03294-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"458_CR258","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/annonc\/mdw552","volume":"28","author":"D Morel","year":"2017","unstructured":"Morel D, Almouzni G, Soria JC, Postel-Vinay S. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Ann Oncol. 2017;28(2):254\u201369. https:\/\/doi.org\/10.1093\/annonc\/mdw552.","journal-title":"Ann Oncol"},{"key":"458_CR259","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","volume":"65","author":"S Gomez","year":"2020","unstructured":"Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99\u2013113. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.019.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"458_CR260","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284-300.e21. https:\/\/doi.org\/10.1016\/j.cell.2017.10.022.","journal-title":"Cell"},{"issue":"1","key":"458_CR261","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-022-02530-y","volume":"41","author":"MJ Kling","year":"2022","unstructured":"Kling MJ, Kesherwani V, Mishra NK, Alexander G, McIntyre EM, Ray S, et al. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. J Exp Clin Cancer Res. 2022;41(1):321. https:\/\/doi.org\/10.1186\/s13046-022-02530-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"458_CR262","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/hep.31642","volume":"73","author":"L Colyn","year":"2021","unstructured":"Colyn L, B\u00e1rcena-Varela M, \u00c1lvarez-Sola G, Latasa MU, Uriarte I, Santamar\u00eda E, et al. Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Hepatology. 2021;73(6):2380\u201396. https:\/\/doi.org\/10.1002\/hep.31642.","journal-title":"Hepatology"},{"issue":"22","key":"458_CR263","doi-asserted-by":"publisher","first-page":"11527","DOI":"10.1093\/nar\/gkz1083","volume":"47","author":"L Wang","year":"2019","unstructured":"Wang L, Lee JY, Gao L, Yin J, Duan Y, Jimenez LA, et al. A DNA aptamer for binding and inhibition of DNA methyltransferase 1. Nucleic Acids Res. 2019;47(22):11527\u201337. https:\/\/doi.org\/10.1093\/nar\/gkz1083.","journal-title":"Nucleic Acids Res"},{"issue":"29","key":"458_CR264","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505567","volume":"12","author":"X Yang","year":"2025","unstructured":"Yang X, Xu C, Zeng Y, Wang C, Gao Y, Ding J, et al. Pyroptosis-Inducing Platinum(IV) prodrugs via GSDME pathway for chemoimmunotherapy and metastasis inhibition in triple-negative breast cancer. Adv Sci (Weinh). 2025;12(29):e05567. https:\/\/doi.org\/10.1002\/advs.202505567.","journal-title":"Adv Sci (Weinh)"},{"issue":"51","key":"458_CR265","doi-asserted-by":"publisher","first-page":"21450","DOI":"10.1021\/jacs.0c10324","volume":"142","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Chen G, Li XM, Liu S, Tian G, Li Y, et al. Selective targeting of AF9 YEATS domain by cyclopeptide inhibitors with preorganized conformation. J Am Chem Soc. 2020;142(51):21450\u20139. https:\/\/doi.org\/10.1021\/jacs.0c10324.","journal-title":"J Am Chem Soc"},{"issue":"4","key":"458_CR266","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/med.21942","volume":"43","author":"A Divakaran","year":"2023","unstructured":"Divakaran A, Harki DA, Pomerantz WCK. Recent progress and structural analyses of domain-selective BET inhibitors. Med Res Rev. 2023;43(4):972\u20131018. https:\/\/doi.org\/10.1002\/med.21942.","journal-title":"Med Res Rev"},{"issue":"1","key":"458_CR267","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41375-022-01765-0","volume":"37","author":"H Hu","year":"2023","unstructured":"Hu H, Saha N, Yang Y, Ahmad E, Lachowski L, Shrestha U, et al. The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia. Leukemia. 2023;37(1):190\u2013201. https:\/\/doi.org\/10.1038\/s41375-022-01765-0.","journal-title":"Leukemia"},{"issue":"1","key":"458_CR268","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/s41467-020-16443-x","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Huang J, Zhang C, Zhao F, Kim W, Tu X, et al. The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair. Nat Commun. 2020;11(1):2639. https:\/\/doi.org\/10.1038\/s41467-020-16443-x.","journal-title":"Nat Commun"},{"issue":"4","key":"458_CR269","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41588-020-0590-9","volume":"52","author":"KH Lin","year":"2020","unstructured":"Lin KH, Rutter JC, Xie A, Pardieu B, Winn ET, Bello RD, et al. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. Nat Genet. 2020;52(4):408\u201317. https:\/\/doi.org\/10.1038\/s41588-020-0590-9.","journal-title":"Nat Genet"},{"key":"458_CR270","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107631","volume":"215","author":"F Spriano","year":"2020","unstructured":"Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: the example of lymphomas. Pharmacol Ther. 2020;215:107631. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107631.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"458_CR271","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/med.21859","volume":"42","author":"L Feng","year":"2022","unstructured":"Feng L, Wang G, Chen Y, He G, Liu B, Liu J, et al. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives. Med Res Rev. 2022;42(2):710\u201343. https:\/\/doi.org\/10.1002\/med.21859.","journal-title":"Med Res Rev"},{"issue":"8","key":"458_CR272","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41594-018-0102-0","volume":"25","author":"H Rahnamoun","year":"2018","unstructured":"Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey KM, Komives EA, et al. RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. Nat Struct Mol Biol. 2018;25(8):687\u201397. https:\/\/doi.org\/10.1038\/s41594-018-0102-0.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"458_CR273","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","volume":"9","author":"H Qian","year":"2023","unstructured":"Qian H, Zhu M, Tan X, Zhang Y, Liu X, Yang L. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets. Cell Death Discov. 2023;9(1):470. https:\/\/doi.org\/10.1038\/s41420-023-01775-6.","journal-title":"Cell Death Discov"},{"issue":"1","key":"458_CR274","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13046-024-03031-w","volume":"43","author":"P Fonseca","year":"2024","unstructured":"Fonseca P, Cui W, Struyf N, Tong L, Chaurasiya A, Casagrande F, et al. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells. J Exp Clin Cancer Res. 2024;43(1):107. https:\/\/doi.org\/10.1186\/s13046-024-03031-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"458_CR275","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1158\/1078-0432.Ccr-25-1406","volume":"31","author":"R Liu","year":"2025","unstructured":"Liu R, Wang X, Branigan TB, Griffin D, McSweeney C, Hao J, et al. BET bromodomain inhibition reverses CDK4\/6 inhibitor resistance in estrogen receptor-positive breast cancer via induction of miR-34a-5p. Clin Cancer Res. 2025;31(23):5096\u2013110. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-1406.","journal-title":"Clin Cancer Res"},{"key":"458_CR276","doi-asserted-by":"publisher","unstructured":"Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med. 2017;9(400). https:\/\/doi.org\/10.1126\/scitranslmed.aal1645.","DOI":"10.1126\/scitranslmed.aal1645"},{"issue":"1","key":"458_CR277","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.Cd-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8(1):24\u201336. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0605.","journal-title":"Cancer Discov"},{"key":"458_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107479","volume":"208","author":"O Bechter","year":"2020","unstructured":"Bechter O, Sch\u00f6ffski P. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors. Pharmacol Ther. 2020;208:107479. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107479.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"458_CR279","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/0008-5472.Can-23-0291","volume":"84","author":"AJ Monteith","year":"2024","unstructured":"Monteith AJ, Ramsey HE, Silver AJ, Brown D, Greenwood D, Smith BN, et al. Lactate utilization enables metabolic escape to confer resistance to BET inhibition in acute myeloid leukemia. Cancer Res. 2024;84(7):1101\u201314. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-0291.","journal-title":"Cancer Res"},{"issue":"2","key":"458_CR280","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.molcel.2016.03.028","volume":"62","author":"Y Li","year":"2016","unstructured":"Li Y, Sabari BR, Panchenko T, Wen H, Zhao D, Guan H, et al. Molecular coupling of histone crotonylation and active transcription by AF9 YEATS domain. Mol Cell. 2016;62(2):181\u201393. https:\/\/doi.org\/10.1016\/j.molcel.2016.03.028.","journal-title":"Mol Cell"},{"issue":"5","key":"458_CR281","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1021\/acscentsci.0c01550","volume":"7","author":"L Garnar-Wortzel","year":"2021","unstructured":"Garnar-Wortzel L, Bishop TR, Kitamura S, Milosevich N, Asiaban JN, Zhang X, et al. Chemical inhibition of ENL\/AF9 YEATS domains in acute leukemia. ACS Cent Sci. 2021;7(5):815\u201330. https:\/\/doi.org\/10.1021\/acscentsci.0c01550.","journal-title":"ACS Cent Sci"},{"issue":"50","key":"458_CR282","doi-asserted-by":"publisher","first-page":"16302","DOI":"10.1002\/anie.201810617","volume":"57","author":"M Moustakim","year":"2018","unstructured":"Moustakim M, Christott T, Monteiro OP, Bennett J, Giroud C, Ward J, et al. Discovery of an MLLT1\/3 YEATS domain chemical probe. Angew Chem Int Ed Engl. 2018;57(50):16302\u20137. https:\/\/doi.org\/10.1002\/anie.201810617.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"12","key":"458_CR283","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41589-018-0144-y","volume":"14","author":"X Li","year":"2018","unstructured":"Li X, Li XM, Jiang Y, Liu Z, Cui Y, Fung KY, et al. Structure-guided development of YEATS domain inhibitors by targeting \u03c0-\u03c0-\u03c0 stacking. Nat Chem Biol. 2018;14(12):1140\u20139. https:\/\/doi.org\/10.1038\/s41589-018-0144-y.","journal-title":"Nat Chem Biol"},{"issue":"17","key":"458_CR284","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.7150\/thno.56737","volume":"11","author":"F Wu","year":"2021","unstructured":"Wu F, Nie S, Yao Y, Huo T, Li X, Wu X, et al. Small-molecule inhibitor of AF9\/ENL-DOT1L\/AF4\/AFF4 interactions suppresses malignant gene expression and tumor growth. Theranostics. 2021;11(17):8172\u201384. https:\/\/doi.org\/10.7150\/thno.56737.","journal-title":"Theranostics"},{"issue":"1","key":"458_CR285","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-022-01258-8","volume":"15","author":"X Li","year":"2022","unstructured":"Li X, Yao Y, Wu F, Song Y. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. J Hematol Oncol. 2022;15(1):41. https:\/\/doi.org\/10.1186\/s13045-022-01258-8.","journal-title":"J Hematol Oncol"},{"issue":"7788","key":"458_CR286","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-019-1842-7","volume":"577","author":"L Wan","year":"2020","unstructured":"Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature. 2020;577(7788):121\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1842-7.","journal-title":"Nature"},{"issue":"5","key":"458_CR287","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2017.04.005","volume":"31","author":"L Xia","year":"2017","unstructured":"Xia L, Huang W, Bellani M, Seidman MM, Wu K, Fan D, et al. CHD4 has oncogenic functions in initiating and maintaining epigenetic suppression of multiple tumor suppressor genes. Cancer Cell. 2017;31(5):653-68.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.005.","journal-title":"Cancer Cell"},{"issue":"7612","key":"458_CR288","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382\u20137. https:\/\/doi.org\/10.1038\/nature18325.","journal-title":"Nature"},{"issue":"2","key":"458_CR289","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1158\/0008-5472.Can-22-3950","volume":"84","author":"J Graca Marques","year":"2024","unstructured":"Graca Marques J, Pavlovic B, Ngo QA, Pedot G, Roemmele M, Volken L, et al. The Chromatin Remodeler CHD4 sustains ewing sarcoma cell survival by controlling global chromatin architecture. Cancer Res. 2024;84(2):241\u201357. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-3950.","journal-title":"Cancer Res"},{"issue":"6","key":"458_CR290","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/nar\/gkaa006","volume":"48","author":"T Hou","year":"2020","unstructured":"Hou T, Cao Z, Zhang J, Tang M, Tian Y, Li Y, et al. SIRT6 coordinates with CHD4 to promote chromatin relaxation and DNA repair. Nucleic Acids Res. 2020;48(6):2982\u20133000. https:\/\/doi.org\/10.1093\/nar\/gkaa006.","journal-title":"Nucleic Acids Res"},{"key":"458_CR291","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100913","volume":"66","author":"J Wu","year":"2023","unstructured":"Wu J, Zhou Z, Li J, Liu H, Zhang H, Zhang J, et al. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK\/ERK axis. Drug Resist Updat. 2023;66:100913. https:\/\/doi.org\/10.1016\/j.drup.2022.100913.","journal-title":"Drug Resist Updat"},{"issue":"21","key":"458_CR292","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.Can-16-0854","volume":"76","author":"Y Yokoyama","year":"2016","unstructured":"Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, et al. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Res. 2016;76(21):6320\u201330. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-0854.","journal-title":"Cancer Res"},{"issue":"6","key":"458_CR293","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","volume":"34","author":"AB Iniguez","year":"2018","unstructured":"Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, et al. Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling. Cancer Cell. 2018;34(6):922-38.e7. https:\/\/doi.org\/10.1016\/j.ccell.2018.11.005.","journal-title":"Cancer Cell"},{"issue":"8","key":"458_CR294","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/0008-5472.Can-23-1836","volume":"84","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ying Y, Ma W, Ma H, Shi L, Gao X, et al. Targeting the epigenetic reader ENL inhibits super-enhancer-driven oncogenic transcription and synergizes with BET inhibition to suppress tumor progression. Cancer Res. 2024;84(8):1237\u201351. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-1836.","journal-title":"Cancer Res"},{"issue":"11","key":"458_CR295","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/circulationaha.125.073833","volume":"152","author":"ME Sweat","year":"2025","unstructured":"Sweat ME, Shi W, Sweat YY, Li J, Li J, Keating EM, et al. TBX5 and CHD4 coordinately activate atrial cardiomyocyte genes to maintain cardiac rhythm homeostasis. Circulation. 2025;152(11):784\u2013801. https:\/\/doi.org\/10.1161\/circulationaha.125.073833.","journal-title":"Circulation"},{"issue":"19","key":"458_CR296","doi-asserted-by":"publisher","first-page":"11587","DOI":"10.1093\/nar\/gkae798","volume":"52","author":"M Altinbay","year":"2024","unstructured":"Altinbay M, Wang J, Chen J, Sch\u00e4fer D, Sprang M, Blagojevic B, et al. Chem-CRISPR\/dCas9FCPF: a platform for chemically induced epigenome editing. Nucleic Acids Res. 2024;52(19):11587\u2013601. https:\/\/doi.org\/10.1093\/nar\/gkae798.","journal-title":"Nucleic Acids Res"},{"key":"458_CR297","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.semcancer.2020.12.018","volume":"83","author":"I Ansari","year":"2022","unstructured":"Ansari I, Chaturvedi A, Chitkara D, Singh S. CRISPR\/Cas mediated epigenome editing for cancer therapy. Semin Cancer Biol. 2022;83:570\u201383. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.018.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"458_CR298","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1093\/nar\/gkac123","volume":"50","author":"H O'Geen","year":"2022","unstructured":"O\u2019Geen H, Tomkova M, Combs JA, Tilley EK, Segal DJ. Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing. Nucleic Acids Res. 2022;50(6):3239\u201353. https:\/\/doi.org\/10.1093\/nar\/gkac123.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"458_CR299","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","volume":"18","author":"MP Gemberling","year":"2021","unstructured":"Gemberling MP, Siklenka K, Rodriguez E, Tonn-Eisinger KR, Barrera A, Liu F, et al. Transgenic mice for in vivo epigenome editing with CRISPR-based systems. Nat Methods. 2021;18(8):965\u201374. https:\/\/doi.org\/10.1038\/s41592-021-01207-2.","journal-title":"Nat Methods"},{"issue":"5","key":"458_CR300","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1164\/rccm.201711-2242OC","volume":"198","author":"J Qu","year":"2018","unstructured":"Qu J, Zhu L, Zhou Z, Chen P, Liu S, Locy ML, et al. Reversing mechanoinductive DSP expression by CRISPR\/dCas9-mediated epigenome editing. Am J Respir Crit Care Med. 2018;198(5):599\u2013609. https:\/\/doi.org\/10.1164\/rccm.201711-2242OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"458_CR301","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jare.2024.10.027","volume":"75","author":"M Huang","year":"2025","unstructured":"Huang M, Wang K, Li A, Zhu X, Zhou Z, Yang C, et al. Mini and enhanced CRISPR activators for cancer therapies. J Adv Res. 2025;75:151\u201361. https:\/\/doi.org\/10.1016\/j.jare.2024.10.027.","journal-title":"J Adv Res"},{"issue":"41","key":"458_CR302","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202102494","volume":"17","author":"H Lu","year":"2021","unstructured":"Lu H, Zhang Q, He S, Liu S, Xie Z, Li X, et al. Reduction-Sensitive Fluorinated-Pt(IV) universal transfection nanoplatform facilitating CT45-targeted CRISPR\/dCas9 activation for synergistic and individualized treatment of ovarian cancer. Small. 2021;17(41):e2102494. https:\/\/doi.org\/10.1002\/smll.202102494.","journal-title":"Small"},{"issue":"11","key":"458_CR303","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41590-019-0500-4","volume":"20","author":"G Wang","year":"2019","unstructured":"Wang G, Chow RD, Bai Z, Zhu L, Errami Y, Dai X, et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat Immunol. 2019;20(11):1494\u2013505. https:\/\/doi.org\/10.1038\/s41590-019-0500-4.","journal-title":"Nat Immunol"},{"issue":"9","key":"458_CR304","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","volume":"184","author":"JK Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184(9):2503-19.e17. https:\/\/doi.org\/10.1016\/j.cell.2021.03.025.","journal-title":"Cell"},{"issue":"6","key":"458_CR305","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/neuonc\/noaf055","volume":"27","author":"K Lin","year":"2025","unstructured":"Lin K, Zou C, Hubbard A, Sengelmann S, Goudy L, Wang IC, et al. Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy. Neuro Oncol. 2025;27(6):1443\u201357. https:\/\/doi.org\/10.1093\/neuonc\/noaf055.","journal-title":"Neuro Oncol"},{"key":"458_CR306","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02856-w","author":"L Goudy","year":"2025","unstructured":"Goudy L, Ha A, Borah AA, Umhoefer JM, Chow L, Tran C, et al. Integrated epigenetic and genetic programming of primary human T cells. Nat Biotechnol. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02856-w.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"458_CR307","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.7150\/thno.92526","volume":"14","author":"XJ Dai","year":"2024","unstructured":"Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, et al. Degraders in epigenetic therapy: PROTACs and beyond. Theranostics. 2024;14(4):1464\u201399. https:\/\/doi.org\/10.7150\/thno.92526.","journal-title":"Theranostics"},{"issue":"36","key":"458_CR308","doi-asserted-by":"publisher","first-page":"15448","DOI":"10.1002\/anie.202004310","volume":"59","author":"LM Luh","year":"2020","unstructured":"Luh LM, Scheib U, Juenemann K, Wortmann L, Brands M, Cromm PM. Prey for the proteasome: targeted protein degradation-A medicinal chemist\u2019s perspective. Angew Chem Int Ed Engl. 2020;59(36):15448\u201366. https:\/\/doi.org\/10.1002\/anie.202004310.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"D1","key":"458_CR309","doi-asserted-by":"publisher","first-page":"D1381","DOI":"10.1093\/nar\/gkaa807","volume":"49","author":"G Weng","year":"2021","unstructured":"Weng G, Shen C, Cao D, Gao J, Dong X, He Q, et al. PROTAC-DB: an online database of PROTACs. Nucleic Acids Res. 2021;49(D1):D1381\u20137. https:\/\/doi.org\/10.1093\/nar\/gkaa807.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"458_CR310","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-021-00245-x","volume":"20","author":"M Schneider","year":"2021","unstructured":"Schneider M, Radoux CJ, Hercules A, Ochoa D, Dunham I, Zalmas LP, et al. The PROTACtable genome. Nat Rev Drug Discov. 2021;20(10):789\u201397. https:\/\/doi.org\/10.1038\/s41573-021-00245-x.","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"458_CR311","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1039\/d3cs00100h","volume":"52","author":"M Kabir","year":"2023","unstructured":"Kabir M, Yu X, Kaniskan H, Jin J. Chemically induced degradation of epigenetic targets. Chem Soc Rev. 2023;52(13):4313\u201342. https:\/\/doi.org\/10.1039\/d3cs00100h.","journal-title":"Chem Soc Rev"},{"issue":"9","key":"458_CR312","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/leu.2016.393","volume":"31","author":"DT Saenz","year":"2017","unstructured":"Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017;31(9):1951\u201361. https:\/\/doi.org\/10.1038\/leu.2016.393.","journal-title":"Leukemia"},{"issue":"21","key":"458_CR313","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202313460","volume":"36","author":"D Huang","year":"2024","unstructured":"Huang D, Zou Y, Huang H, Yin J, Long S, Sun W, et al. A PROTAC augmenter for photo-driven pyroptosis in breast cancer. Adv Mater. 2024;36(21):e2313460. https:\/\/doi.org\/10.1002\/adma.202313460.","journal-title":"Adv Mater"},{"issue":"3","key":"458_CR314","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","volume":"24","author":"J Wang","year":"2022","unstructured":"Wang J, Yu X, Gong W, Liu X, Park KS, Ma A, et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol. 2022;24(3):384\u201399. https:\/\/doi.org\/10.1038\/s41556-022-00850-x.","journal-title":"Nat Cell Biol"},{"issue":"42","key":"458_CR315","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202310059","volume":"62","author":"C Zhao","year":"2023","unstructured":"Zhao C, Chen S, Chen D, R\u00edo-Berg\u00e9 C, Zhang J, Van Der Wouden PE, et al. Histone deacetylase 3-directed PROTACs have anti-inflammatory potential by blocking polarization of M0-like into M1-like macrophages. Angew Chem Int Ed Engl. 2023;62(42):e202310059. https:\/\/doi.org\/10.1002\/anie.202310059.","journal-title":"Angew Chem Int Ed Engl"},{"key":"458_CR316","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","volume":"64","author":"V Oleinikovas","year":"2024","unstructured":"Oleinikovas V, Gainza P, Ryckmans T, Fasching B, Thom\u00e4 NH. From thalidomide to rational molecular glue design for targeted protein degradation. Annu Rev Pharmacol Toxicol. 2024;64:291\u2013312. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022123-104147.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"458_CR317","doi-asserted-by":"publisher","unstructured":"Yoon H, Rutter JC, Li YD, Ebert BL. Induced protein degradation for therapeutics: past, present, and future. J Clin Invest. 2024;134(1). https:\/\/doi.org\/10.1172\/jci175265.","DOI":"10.1172\/jci175265"},{"issue":"7824","key":"458_CR318","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","volume":"585","author":"M S\u0142abicki","year":"2020","unstructured":"S\u0142abicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020;585(7824):293\u20137. https:\/\/doi.org\/10.1038\/s41586-020-2374-x.","journal-title":"Nature"},{"issue":"5","key":"458_CR319","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","volume":"9","author":"ES Toriki","year":"2023","unstructured":"Toriki ES, Papatzimas JW, Nishikawa K, Dovala D, Frank AO, Hesse MJ, et al. Rational chemical design of molecular glue degraders. ACS Cent Sci. 2023;9(5):915\u201326. https:\/\/doi.org\/10.1021\/acscentsci.2c01317.","journal-title":"ACS Cent Sci"},{"issue":"1","key":"458_CR320","doi-asserted-by":"publisher","first-page":"7259","DOI":"10.1038\/s41467-024-50515-6","volume":"15","author":"B Kantor","year":"2024","unstructured":"Kantor B, O\u2019Donovan B, Rittiner J, Hodgson D, Lindner N, Guerrero S, et al. The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders. Nat Commun. 2024;15(1):7259. https:\/\/doi.org\/10.1038\/s41467-024-50515-6.","journal-title":"Nat Commun"},{"issue":"5","key":"458_CR321","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"458_CR322","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","volume":"42","author":"JR Davis","year":"2024","unstructured":"Davis JR, Banskota S, Levy JM, Newby GA, Wang X, Anzalone AV, et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat Biotechnol. 2024;42(2):253\u201364. https:\/\/doi.org\/10.1038\/s41587-023-01758-z.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"458_CR323","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.molcel.2018.12.003","volume":"73","author":"A Edraki","year":"2019","unstructured":"Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song CQ, et al. A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing. Mol Cell. 2019;73(4):714-26.e4. https:\/\/doi.org\/10.1016\/j.molcel.2018.12.003.","journal-title":"Mol Cell"},{"issue":"6","key":"458_CR324","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.ymthe.2024.12.012","volume":"33","author":"A Westhaus","year":"2025","unstructured":"Westhaus A, Barba-Sarasua E, Chen Y, Hsu K, Scott S, Knight M, et al. Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation. Mol Ther. 2025;33(6):2801\u201318. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.012.","journal-title":"Mol Ther"},{"issue":"18","key":"458_CR325","doi-asserted-by":"publisher","first-page":"10059","DOI":"10.1093\/nar\/gkad676","volume":"51","author":"J Haldrup","year":"2023","unstructured":"Haldrup J, Andersen S, Labial ARL, Wolff JH, Frandsen FP, Skov TW, et al. Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR\/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Res. 2023;51(18):10059\u201374. https:\/\/doi.org\/10.1093\/nar\/gkad676.","journal-title":"Nucleic Acids Res"},{"key":"458_CR326","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","volume":"370","author":"JB Simonsen","year":"2024","unstructured":"Simonsen JB. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities. J Control Release. 2024;370:763\u201372. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.022.","journal-title":"J Control Release"},{"issue":"32","key":"458_CR327","doi-asserted-by":"publisher","first-page":"28595","DOI":"10.1021\/jacs.5c08345","volume":"147","author":"CK De","year":"2025","unstructured":"De CK, Tsuda M, Zhu C, Dehn S, Hinrichs H, Tsuji N, et al. The overlooked stereoisomers of the ionizable lipid ALC315. J Am Chem Soc. 2025;147(32):28595\u2013600. https:\/\/doi.org\/10.1021\/jacs.5c08345.","journal-title":"J Am Chem Soc"},{"issue":"14","key":"458_CR328","doi-asserted-by":"publisher","first-page":"13685","DOI":"10.1021\/acsnano.4c14625","volume":"19","author":"G Zhao","year":"2025","unstructured":"Zhao G, Zeng Y, Cheng W, Karkampouna S, Papadopoulou P, Hu B, et al. Peptide-modified lipid nanoparticles boost the antitumor efficacy of RNA therapeutics. ACS Nano. 2025;19(14):13685\u2013704. https:\/\/doi.org\/10.1021\/acsnano.4c14625.","journal-title":"ACS Nano"},{"key":"458_CR329","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113835","volume":"176","author":"W Ke","year":"2021","unstructured":"Ke W, Afonin KA. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Adv Drug Deliv Rev. 2021;176:113835. https:\/\/doi.org\/10.1016\/j.addr.2021.113835.","journal-title":"Adv Drug Deliv Rev"},{"issue":"44","key":"458_CR330","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202507608","volume":"37","author":"Q Dou","year":"2025","unstructured":"Dou Q, Wang J, Mao M, Shui L, Hu TY, Zhang Y. Engineered virus-like nanoparticles enable multimodal protein degradation for enhanced tumor therapy. Adv Mater. 2025;37(44):e07608. https:\/\/doi.org\/10.1002\/adma.202507608.","journal-title":"Adv Mater"},{"issue":"4","key":"458_CR331","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.molcel.2019.07.013","volume":"75","author":"C Mayor-Ruiz","year":"2019","unstructured":"Mayor-Ruiz C, Jaeger MG, Bauer S, Brand M, Sin C, Hanzl A, et al. Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation. Mol Cell. 2019;75(4):849-58.e8. https:\/\/doi.org\/10.1016\/j.molcel.2019.07.013.","journal-title":"Mol Cell"},{"key":"458_CR332","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jconrel.2021.12.003","volume":"341","author":"AS Elz","year":"2022","unstructured":"Elz AS, Trevaskis NL, Porter CJH, Bowen JM, Prestidge CA. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. J Control Release. 2022;341:676\u2013701. https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.003.","journal-title":"J Control Release"},{"issue":"28","key":"458_CR333","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202503958","volume":"64","author":"AG Baker","year":"2025","unstructured":"Baker AG, Ho APT, Itzhaki LS, Fruk L. Nanoparticle-mediated targeted protein degradation: an emerging therapeutics technology. Angew Chem Int Ed Engl. 2025;64(28):e202503958. https:\/\/doi.org\/10.1002\/anie.202503958.","journal-title":"Angew Chem Int Ed Engl"},{"key":"458_CR334","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2025.108750","volume":"86","author":"YY Xu","year":"2026","unstructured":"Xu YY, Zhou SM, Wang LY, Zhang R, Li K, Qian ZY, et al. Methods for detecting off-target effects of CRISPR\/Cas9. Biotechnol Adv. 2026;86:108750. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108750.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"458_CR335","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ymthe.2022.10.009","volume":"31","author":"X Huang","year":"2023","unstructured":"Huang X, Wang M, Wu X, Zou Y, Xu J, Cao C, et al. Screening DNA aptamers that control the DNA cleavage, homology-directed repair, and transcriptional regulation of the CRISPR-(d)Cas9 system. Mol Ther. 2023;31(1):260\u20138. https:\/\/doi.org\/10.1016\/j.ymthe.2022.10.009.","journal-title":"Mol Ther"},{"issue":"25","key":"458_CR336","doi-asserted-by":"publisher","first-page":"14155","DOI":"10.1021\/jacs.3c05159","volume":"145","author":"M Chang","year":"2023","unstructured":"Chang M, Gao F, Pontigon D, Gnawali G, Xu H, Wang W. Bioorthogonal PROTAC prodrugs enabled by on-target activation. J Am Chem Soc. 2023;145(25):14155\u201363. https:\/\/doi.org\/10.1021\/jacs.3c05159.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"458_CR337","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","volume":"23","author":"C Wang","year":"2024","unstructured":"Wang C, Zhang Y, Chen W, Wu Y, Xing D. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Mol Cancer. 2024;23(1):110. https:\/\/doi.org\/10.1186\/s12943-024-02024-9.","journal-title":"Mol Cancer"},{"issue":"8","key":"458_CR338","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","volume":"58","author":"S He","year":"2025","unstructured":"He S, Dong G, Sheng C. Strategies for precise modulation of protein degradation. Acc Chem Res. 2025;58(8):1236\u201348. https:\/\/doi.org\/10.1021\/acs.accounts.5c00003.","journal-title":"Acc Chem Res"},{"issue":"1","key":"458_CR339","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","volume":"14","author":"RP Wurz","year":"2023","unstructured":"Wurz RP, Rui H, Dellamaggiore K, Ghimire-Rijal S, Choi K, Smither K, et al. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun. 2023;14(1):4177. https:\/\/doi.org\/10.1038\/s41467-023-39904-5.","journal-title":"Nat Commun"},{"issue":"1","key":"458_CR340","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40035-022-00314-0","volume":"11","author":"H Park","year":"2022","unstructured":"Park H, Shin J, Kim Y, Saito T, Saido TC, Kim J. CRISPR\/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer\u2019s disease. Transl Neurodegener. 2022;11(1):41. https:\/\/doi.org\/10.1186\/s40035-022-00314-0.","journal-title":"Transl Neurodegener"},{"issue":"12","key":"458_CR341","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1038\/s41596-022-00741-3","volume":"17","author":"DM Sapozhnikov","year":"2022","unstructured":"Sapozhnikov DM, Szyf M. Enzyme-free targeted DNA demethylation using CRISPR-dCas9-based steric hindrance to identify DNA methylation marks causal to altered gene expression. Nat Protoc. 2022;17(12):2840\u201381. https:\/\/doi.org\/10.1038\/s41596-022-00741-3.","journal-title":"Nat Protoc"},{"key":"458_CR342","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66933-z","author":"L He","year":"2025","unstructured":"He L, Yao Y, You Y, Wei X, Ma Y, Yuan W, et al. Versatile molecular tools enabling customizable DNA methylation editing in Arabidopsis. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-66933-z.","journal-title":"Nat Commun"},{"issue":"12","key":"458_CR343","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41589-024-01741-y","volume":"20","author":"LJ Seabrook","year":"2024","unstructured":"Seabrook LJ, Franco CN, Loy CA, Osman J, Fredlender C, Zimak J, et al. Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins. Nat Chem Biol. 2024;20(12):1566\u201376. https:\/\/doi.org\/10.1038\/s41589-024-01741-y.","journal-title":"Nat Chem Biol"},{"issue":"24","key":"458_CR344","doi-asserted-by":"publisher","first-page":"20989","DOI":"10.1021\/jacs.5c05456","volume":"147","author":"R Zhang","year":"2025","unstructured":"Zhang R, Yang C, Gao X, He Z, Ji DK, Tan W. Phototriggered LYTAC: Photoactive bispecific aptamer chimera enhances targeted degradation of membrane protein through regulating cell autophagy. J Am Chem Soc. 2025;147(24):20989\u20131002. https:\/\/doi.org\/10.1021\/jacs.5c05456.","journal-title":"J Am Chem Soc"},{"issue":"8","key":"458_CR345","doi-asserted-by":"publisher","first-page":"7742","DOI":"10.1021\/acsnano.4c12747","volume":"19","author":"S Lee","year":"2025","unstructured":"Lee S, Kang S, Kim WJ. Targeted protein degradation in cancer therapy via hydrophobic polymer-tagged nanoparticles. ACS Nano. 2025;19(8):7742\u201354. https:\/\/doi.org\/10.1021\/acsnano.4c12747.","journal-title":"ACS Nano"},{"issue":"27","key":"458_CR346","doi-asserted-by":"publisher","first-page":"11734","DOI":"10.1021\/jacs.9b13907","volume":"142","author":"R Gabizon","year":"2020","unstructured":"Gabizon R, Shraga A, Gehrtz P, Livnah E, Shorer Y, Gurwicz N, et al. Efficient targeted degradation via reversible and irreversible covalent PROTACs. J Am Chem Soc. 2020;142(27):11734\u201342. https:\/\/doi.org\/10.1021\/jacs.9b13907.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"458_CR347","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8(1):69. https:\/\/doi.org\/10.1038\/s41392-023-01341-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"458_CR348","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1038\/s41467-019-12983-z","volume":"10","author":"F Caiado","year":"2019","unstructured":"Caiado F, Maia-Silva D, Jardim C, Schmolka N, Carvalho T, Refor\u00e7o C, et al. Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nat Commun. 2019;10(1):4986. https:\/\/doi.org\/10.1038\/s41467-019-12983-z.","journal-title":"Nat Commun"},{"issue":"4","key":"458_CR349","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","volume":"30","author":"NE Muvarak","year":"2016","unstructured":"Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell. 2016;30(4):637\u201350. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.002.","journal-title":"Cancer Cell"},{"issue":"10","key":"458_CR350","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/leu.2017.54","volume":"31","author":"E Viziteu","year":"2017","unstructured":"Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, et al. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia. 2017;31(10):2104\u201313. https:\/\/doi.org\/10.1038\/leu.2017.54.","journal-title":"Leukemia"},{"key":"458_CR351","doi-asserted-by":"publisher","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023;15(722):eadf6732. https:\/\/doi.org\/10.1126\/scitranslmed.adf6732.","DOI":"10.1126\/scitranslmed.adf6732"},{"issue":"1","key":"458_CR352","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17(1):37. https:\/\/doi.org\/10.1186\/s13045-024-01551-8.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"458_CR353","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tips.2017.11.008","volume":"39","author":"I Vancurova","year":"2018","unstructured":"Vancurova I, Uddin MM, Zou Y, Vancura A. Combination therapies targeting HDAC and IKK in solid tumors. Trends Pharmacol Sci. 2018;39(3):295\u2013306. https:\/\/doi.org\/10.1016\/j.tips.2017.11.008.","journal-title":"Trends Pharmacol Sci"},{"issue":"21","key":"458_CR354","doi-asserted-by":"publisher","first-page":"10017","DOI":"10.1093\/nar\/gkw922","volume":"44","author":"WP Roos","year":"2016","unstructured":"Roos WP, Krumm A. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucleic Acids Res. 2016;44(21):10017\u201330. https:\/\/doi.org\/10.1093\/nar\/gkw922.","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"458_CR355","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1182\/blood.2020007401","volume":"138","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li W, Schulz VP, Zhao H, Qu X, Qi Q, et al. Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency. Blood. 2021;138(17):1615\u201327. https:\/\/doi.org\/10.1182\/blood.2020007401.","journal-title":"Blood"},{"issue":"9","key":"458_CR356","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","volume":"24","author":"ML Persson","year":"2022","unstructured":"Persson ML, Douglas AM, Alvaro F, Faridi P, Larsen MR, Alonso MM, et al. The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 2022;24(9):1408\u201322. https:\/\/doi.org\/10.1093\/neuonc\/noac117.","journal-title":"Neuro Oncol"},{"issue":"3","key":"458_CR357","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaoncol.2021.5970","volume":"8","author":"A Sadagopan","year":"2022","unstructured":"Sadagopan A, Michelakos T, Boyiadzis G, Ferrone C, Ferrone S. Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the era of checkpoint inhibitors: a review. JAMA Oncol. 2022;8(3):462\u201373. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5970.","journal-title":"JAMA Oncol"},{"issue":"11","key":"458_CR358","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1158\/2159-8290.Cd-21-0506","volume":"11","author":"R Chen","year":"2021","unstructured":"Chen R, Ishak CA, De Carvalho DD. Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis. Cancer Discov. 2021;11(11):2707\u201325. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0506.","journal-title":"Cancer Discov"},{"issue":"1","key":"458_CR359","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tcb.2018.07.006","volume":"29","author":"H Loo Yau","year":"2019","unstructured":"Loo Yau H, Ettayebi I, De Carvalho DD. The cancer epigenome: exploiting its vulnerabilities for immunotherapy. Trends Cell Biol. 2019;29(1):31\u201343. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.006.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"458_CR360","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20(1):171. https:\/\/doi.org\/10.1186\/s12943-021-01464-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"458_CR361","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s40425-019-0758-y","volume":"7","author":"W Mao","year":"2019","unstructured":"Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, et al. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. J Immunother Cancer. 2019;7(1):277. https:\/\/doi.org\/10.1186\/s40425-019-0758-y.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"458_CR362","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jtho.2024.12.020","volume":"20","author":"X Zhao","year":"2025","unstructured":"Zhao X, Liu B, William WN, Tsanov KM, Ho YJ, Barriga FM, et al. Interferon epsilon loss is elusive 9p21 link to immune-cold tumors, resistant to immune checkpoint therapy, and endogenous CXCL9\/10 induction. J Thorac Oncol. 2025;20(9):1177\u2013236. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.020.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"458_CR363","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity. 2023;56(7):1613-30.e5. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.003.","journal-title":"Immunity"},{"issue":"7798","key":"458_CR364","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","volume":"579","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284\u201390. https:\/\/doi.org\/10.1038\/s41586-020-2054-x.","journal-title":"Nature"},{"issue":"6718","key":"458_CR365","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1126\/science.ads6217","volume":"386","author":"C Tsui","year":"2024","unstructured":"Tsui C, Kallies A. Unwrapping stemness to revive T cells. Science. 2024;386(6718):148\u20139. https:\/\/doi.org\/10.1126\/science.ads6217.","journal-title":"Science"},{"key":"458_CR366","doi-asserted-by":"publisher","unstructured":"Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. J Clin Invest. 2021;131(16). https:\/\/doi.org\/10.1172\/jci145459.","DOI":"10.1172\/jci145459"},{"issue":"3","key":"458_CR367","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41375-023-01808-0","volume":"37","author":"KA Romine","year":"2023","unstructured":"Romine KA, MacPherson K, Cho HJ, Kosaka Y, Flynn PA, Byrd KH, et al. BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8(+) T cells. Leukemia. 2023;37(3):580\u201392. https:\/\/doi.org\/10.1038\/s41375-023-01808-0.","journal-title":"Leukemia"},{"issue":"1","key":"458_CR368","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","volume":"12","author":"L Ny","year":"2021","unstructured":"Ny L, Jespersen H, Karlsson J, Als\u00e9n S, Filges S, All-Eriksson C, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun. 2021;12(1):5155. https:\/\/doi.org\/10.1038\/s41467-021-25332-w.","journal-title":"Nat Commun"},{"issue":"7","key":"458_CR369","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","volume":"25","author":"C Segovia","year":"2019","unstructured":"Segovia C, San Jos\u00e9-En\u00e9riz E, Munera-Maravilla E, Mart\u00ednez-Fern\u00e1ndez M, Garate L, Miranda E, et al. Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25(7):1073\u201381. https:\/\/doi.org\/10.1038\/s41591-019-0499-y.","journal-title":"Nat Med"},{"issue":"2","key":"458_CR370","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/0008-5472.Can-16-0834","volume":"77","author":"T Sato","year":"2017","unstructured":"Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, et al. Transcriptional selectivity of epigenetic therapy in cancer. Cancer Res. 2017;77(2):470\u201381. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-0834.","journal-title":"Cancer Res"},{"issue":"2","key":"458_CR371","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/hep.30168","volume":"69","author":"M B\u00e1rcena-Varela","year":"2019","unstructured":"B\u00e1rcena-Varela M, Caruso S, Llerena S, \u00c1lvarez-Sola G, Uriarte I, Latasa MU, et al. Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology. 2019;69(2):587\u2013603. https:\/\/doi.org\/10.1002\/hep.30168.","journal-title":"Hepatology"},{"issue":"9","key":"458_CR372","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.ccell.2022.08.011","volume":"40","author":"D Akhoundova","year":"2022","unstructured":"Akhoundova D, Rubin MA. Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell. 2022;40(9):920\u201338. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.011.","journal-title":"Cancer Cell"},{"issue":"3","key":"458_CR373","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2018.07.012","volume":"34","author":"E Stewart","year":"2018","unstructured":"Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, et al. Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic, epigenomic, and proteomic analyses. Cancer Cell. 2018;34(3):411-26.e19. https:\/\/doi.org\/10.1016\/j.ccell.2018.07.012.","journal-title":"Cancer Cell"},{"issue":"1","key":"458_CR374","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14(1):101. https:\/\/doi.org\/10.1186\/s13073-022-01102-1.","journal-title":"Genome Med"},{"issue":"2","key":"458_CR375","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17(2):75\u201390. https:\/\/doi.org\/10.1038\/s41571-019-0266-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7894","key":"458_CR376","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"SJ Sammut","year":"2022","unstructured":"Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature. 2022;601(7894):623\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04278-5.","journal-title":"Nature"},{"issue":"9","key":"458_CR377","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1016\/j.apsb.2025.07.030","volume":"15","author":"F Ren","year":"2025","unstructured":"Ren F, Wei J, Chen Q, Hu M, Yu L, Mi J, et al. Artificial intelligence-driven multi-omics approaches in Alzheimer\u2019s disease: progress, challenges, and future directions. Acta Pharm Sin B. 2025;15(9):4327\u201385. https:\/\/doi.org\/10.1016\/j.apsb.2025.07.030.","journal-title":"Acta Pharm Sin B"},{"issue":"22","key":"458_CR378","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2019003262","volume":"134","author":"KA Fennell","year":"2019","unstructured":"Fennell KA, Bell CC, Dawson MA. Epigenetic therapies in acute myeloid leukemia: where to from here? Blood. 2019;134(22):1891\u2013901. https:\/\/doi.org\/10.1182\/blood.2019003262.","journal-title":"Blood"},{"issue":"8","key":"458_CR379","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, \u00c1lvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 2020;41(8):676\u201391. https:\/\/doi.org\/10.1016\/j.it.2020.06.002.","journal-title":"Trends Immunol"},{"issue":"3","key":"458_CR380","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","volume":"30","author":"H Zeng","year":"2016","unstructured":"Zeng H, Qu J, Jin N, Xu J, Lin C, Chen Y, et al. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell. 2016;30(3):459\u201373. https:\/\/doi.org\/10.1016\/j.ccell.2016.08.001.","journal-title":"Cancer Cell"},{"key":"458_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101312","volume":"84","author":"M Safari","year":"2026","unstructured":"Safari M, Scotto L, Basseville A, Litman T, Xue H, Petrukhin L, et al. Combined HDAC and eIF4A inhibition: a novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug Resist Updat. 2026;84:101312. https:\/\/doi.org\/10.1016\/j.drup.2025.101312.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"458_CR382","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ccell.2025.06.005","volume":"43","author":"A Jassim","year":"2025","unstructured":"Jassim A, Nimmervoll BV, Terranova S, Nathan E, Hu L, Taylor JT, et al. Gene context drift identifies drug targets to mitigate cancer treatment resistance. Cancer Cell. 2025;43(9):1608-21.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.06.005.","journal-title":"Cancer Cell"},{"issue":"9","key":"458_CR383","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102329","volume":"6","author":"E Bayraktar","year":"2025","unstructured":"Bayraktar E, Rodriguez-Aguayo C, Stur E, Kumar S, Mangala LS, Jennings NB, et al. Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. Cell Rep Med. 2025;6(9):102329. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102329.","journal-title":"Cell Rep Med"},{"issue":"2","key":"458_CR384","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.apsb.2023.09.003","volume":"14","author":"X Peng","year":"2024","unstructured":"Peng X, Hu Z, Zeng L, Zhang M, Xu C, Lu B, et al. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies. Acta Pharm Sin B. 2024;14(2):533\u201378. https:\/\/doi.org\/10.1016\/j.apsb.2023.09.003.","journal-title":"Acta Pharm Sin B"},{"key":"458_CR385","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218321","volume":"644","author":"J Yang","year":"2026","unstructured":"Yang J, Zhang M, Gao C, Yao X, Sun C, Zhuang J. The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer. Cancer Lett. 2026;644:218321. https:\/\/doi.org\/10.1016\/j.canlet.2026.218321.","journal-title":"Cancer Lett"},{"issue":"22","key":"458_CR386","doi-asserted-by":"publisher","first-page":"11712","DOI":"10.1093\/nar\/gky847","volume":"46","author":"H Jin","year":"2018","unstructured":"Jin H, Choi SM, Kang MJ, Yun SH, Kwon DJ, Noh YS, et al. Salicylic acid-induced transcriptional reprogramming by the HAC-NPR1-TGA histone acetyltransferase complex in Arabidopsis. Nucleic Acids Res. 2018;46(22):11712\u201325. https:\/\/doi.org\/10.1093\/nar\/gky847.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"458_CR387","doi-asserted-by":"publisher","first-page":"10444","DOI":"10.1038\/s41467-024-54477-7","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Huang Z, Liu Y, He P, Wang Y, Yan L, et al. Ultrasound control of genomic regulatory toolboxes for cancer immunotherapy. Nat Commun. 2024;15(1):10444. https:\/\/doi.org\/10.1038\/s41467-024-54477-7.","journal-title":"Nat Commun"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00458-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:23:23Z","timestamp":1777451003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00458-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":387,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00458-9","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}